Subscribe to “CTRI Bulletin”
Submit a paper

"CTRI Bulletin" #2,(11),2020.

CTRI BULLETIN №2 (11) 2020

Journal Information: Read
Chief Editor: Ergeshov A.E.
Year of foundation: 2017
ISSN (Print): Browse
Publisher site: http://critub.ru
http://tb-bulletin.ru

Return to archive

CONTENT

1)

To the 60th anniversary of Igor Yevgenyevich Tyurin

5 READ MORE
2)

The diagnostics of community-acquired pneumonia in patients with chronic heart failure: a literature review and study outcomes

Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S.

7 READ MORE
3)

Hepatotoxic reactions of TB patients to major TB drugs. The status of the issue

Averbakh М.М.

22 READ MORE
4)

Extraction of Mycobacterium Tuberculosis after in vivo phagocytosis by neutrophils for further genetic and functional analyses

Majorov K.B., Grigorov A.S., Kondratieva E.V., Azhikina T.L., Apt A.S.

30 READ MORE
5)

The peculiarities of exacerbations in patients with different chronic obstructive pulmonary disease phenotypes

Kudryavtseva E.Z., Makaryants N.N., Nikitina L.Yu.

36 READ MORE
6)

Surgical treatment of bronchopleural complications after pneumonectomy in patients with tuberculosis

Giller D.B., Kesaev O.Sh., Ergeshov A.E., Koroyev V.V., Glotov A.A., Gadzhieva P.G., Glotov E.M., Imagozhev Ya.G., Pekhtusov V.A., Nematov O.N.

49 READ MORE
7)

The prevention of post-pneumonectomy mediastinal lung herniation by intraoperative anterior mediastinal plasty in patients with destructive pulmonary TB and the evaluation of its effect on respiratory functions

Ergeshova A.E., Krasnikova E.V., Penagi R.A., Salikhov B.U., Chitorelidze G.V., Tarasov R.V., Bagirov M.A.

60 READ MORE
8)

Different aspects of the internal picture of the disease in adolescents with pulmonary TB

Zolotova N.V., Akhtyamova A.A.

68 READ MORE
9)

The results of immunodiagnostics of tuberculosis in patients admitted to a general hospital pulmonology department

Nebesnaya E.Yu., Bakhshieva L.I., Bagisheva N.V., Dubrovskaya I.I., Zenkova L.A., Mordyk D.I., Moiseeva M.V.

74 READ MORE
10)

A complex approach to treatment of a child with delayed diagnosis of household acquired multidrug resistant pulmonary TB

Gubkina M.F., Sterlikova S.S., Petrakova I.Yu., Khokhlova Yu.Yu., Yukhimenko N.V.

82 READ MORE
11)

Detection of mycobacteria by culture inoculation. Decontamination of diagnostic samples

Sevastyanova E.V., Larionova E.E., Andrievskaya I.Yu., Smirnova T.G.

89 READ MORE
12)

In memory of Victor Petrovich Filippov

100 READ MORE

TO THE 60TH ANNIVERSARY OF IGOR YEVGENYEVICH TYURIN

Article 1.Page 5.
ARTICLE TITLE:

TO THE 60TH ANNIVERSARY OF IGOR YEVGENYEVICH TYURIN

AUTORS: 
DESCRIPTION OF ARTICLE:

Игорь Евгеньевич Тюрин родился в 1960 г. в Ленинграде.

В 1983 г. окончил лечебный факультет Первого Ленинградского Медицинского института им. акад. И.П. Павлова. Сразу после окончания института И.Е. Тюрин работал врачом-интерном, а затем врачом-рентгенологом в рентгенорадиологическом отделении Ленинградской областной клинической больницы. В 1986 г. он был принят в аспирантуру при кафедре рентгенологии и радиологии Военно- медицинской академии. После успешной защиты кандидатской диссертации по рентгенологическим исследованиям легких в реанимации в 1989 г. И.Е. Тюрин стал ассистентом кафедры. В 1997 г. он защитил докторскую диссертацию на тему: ≪Компьютерная томография в диагностике воспалительных заболеваний легких≫ и в 1991 г. был избран доцентом, а в 1997 г. – профессором кафедры рентгенологии и радиологии Военно-медицинской академии.

С 1998 по 2003 гг. И.Е. Тюрин работал в должности профессора кафедры лучевой диагностики и лучевой терапии Санкт-Петербургской государственной медицинской академии им. И.М. Мечникова, одновременно возглавляя отделение лучевой диагностики Ленинградской областной клинической больницы и исполняя обязанности главного специалиста-рентгенолога МЗ Правительства Ленинградской области. В 2001 г. И.Е. Тюрин был назначен главным внештатным специалистом по лучевой диагностике мэрии Санкт-Петербурга.

С 2003 г. И.Е. Тюрин работает в Москве, где был избран на должность заведующего вновь созданной кафедры лучевой диагностики и медицинской физики Российской медицинской академии последипломного образования. Одновременно И.Е. Тюрин стал ведущим научным сотрудником Российского онкологического научного центра им. Н.Н. Блохина. В 2015 г. кафедра была объединена с кафедрой лучевой диагностики РМАПО, а в 2016 г. получила новое название – кафедра рентгенологии и радиологии. И.Е. Тюрин ведет разностороннюю диагностическую консультативную работу, с 2018 г. он по совместительству является главным научным сотрудником ФГБНУ ≪ЦНИИТ≫.

И.Е. Тюрин – член редколлегий ряда медицинских журналов, в том числе ≪Медицинская визуализация≫, ≪Медицинская радиология и радиационная безопасность≫, ≪Интервенционная диагностика и лечение≫, ≪Лучевая диагностика и терапия≫, ≪Вестник ЦНИИТ≫, с 2014 г. он – глав-

ный редактор журнала ≪Вестник рентгенологии и радиологии≫.

И.Е. Тюрин является членом Европейского общества радиологов (ESR), членом Северо-Американского общества радиологов (RSNA), в 2014 г. избран членом исполнительного комитета Европейского общества торакальной визуализации (ESTI). И.Е. Тюрин неоднократно выступал в роли локального организатора школ ESOR в России.

В 2010 г. И.Е. Тюрин организовал и возглавил национальное ≪Общество торакальных радиологов≫, с 2011 г. является членом президиума Российской ассоциации радиологов, в 2016 г. избран вице-президентом этого общества. Был президентом двух конгрессов РАР, международного научного форума ≪Медицинская диагностика≫, Международного конгресса по торакальной радиологии.

И.Е. Тюрин является автором/соавтором более 250 научных работ, в том числе 8 монографий и пособий для врачей, клинических рекомендаций, методических указаний. Под его руководством защищено пять кандидатских и одна докторская диссертация.

В 2010 г. профессор И.Е. Тюрин назначен главным внештатным специалистом лучевым диагностом Минздрава России. Одновременно он является членом экспертного совета и руководителем профильной комиссии по лучевой диагностике при Минздраве России, председателем аттестационной комиссии Минздрава России по профилю ≪лучевая и инструментальная диагностика≫, председателем этического комитета Минздрава России в сфере обращения медицинских изделий.

И.Е. Тюрин снискал заслуженное уважение коллег и многочисленных учеников, он является экспертом высочайшего класса в области торакальной радиологии, обладает широкой эрудицией и охотно делится своими богатыми знаниями с коллегами, оставаясь при этом скромным и приветливым человеком.

Ученики и коллеги, работающие в ФГБНУ ≪ЦНИИТ≫, поздравляют И.Е. Тюрина с 60‑летием

и желают ему крепкого здоровья, многочисленных новых успехов и долгих лет плодотворной работы на благо отечественной медицины и медицинской науки.

REFERENCES: 
KEYWORDS:

Jubilee

FOR CORRESPONDENCE: 

THE DIAGNOSTICS OF COMMUNITY-AC QUIRED PNEUMONIA IN PATIENTS WITH CHRONIC HEART FAILURE: A LITERATURE REVIEW AND STUDY OUTCOMES

Article 2.Page 7.
ARTICLE TITLE:

THE DIAGNOSTICS OF COMMUNITY-AC QUIRED PNEUMONIA IN PATIENTS WITH CHRONIC HEART FAILURE: A LITERATURE REVIEW AND STUDY OUTCOMES

DOI: 10.7868/S2587667820020028

AUTORS:

Bobylev A.A.1,2, Rachina S.A.3, Avdeev S.N.4,5, Kozlov R.S.1,2

1 Smolensk State Medical University, Smolensk, Russia

2 Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy, Smolensk, Russia

3 Peoples’ Friendship University of Russia, Moscow, Russia

4 I.M. Sechenov 1st Moscow State Medical University, Moscow, Russia

5 Pulmonology Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 26.01.2020

Community-acquired pneumonia (CAP) is one of the most common infectious diseases in developed countries. Chronic heart failure (CHF) is an independent risk factor for unfavourable course and poor outcome of CAP. Diagnostics of CAP in CHF patients is associated with objective difficulties. The classical signs of heart failure (dyspnea, fatigue, tachycardia, tachypnea, crepitation in the lungs, pleural effusion) can also be caused by CAP. In addition, the clinical picture of CAP in elderly patients can vary from classical to atypical. Chest X-ray examination remains a standard method of pneumonia diagnostics. However, routine X-ray examination in elderly patients with CHF has technical limitations and low specificity. The multispiral computed tomography (MSCT) of the chest has significantly improved the effectiveness of diagnostics, but it cannot be considered as a baseline alternative to X-ray examination. Etiological verification of pneumonia is difficult due to age-related anatomical and physiological features of elderly patients and limitations for sputum culture. The low systemic inflammatory response in this cohort decreases efficiency of routine laboratory tests (e. g. complete blood count). Challenges in clinical, radiological, microbiological and laboratory diagnostics of CAP in CHF patients suggest use of additional methods, such as evaluation of serum inflammatory biomarkers: C-reactive protein (CRP), procalcitonin (PCT), interleukin-6 (IL-6), tumor necrosis factor-α (TNF-α), etc. These proteins are sensitive and specific indicators of inflammation, and their production sharply increases in various infections (including CAP). Hypersecretion of these biomarkers (but less significant) is also detected in development and progression of blood circulation disorders. CRP is one of the most effective biomarkers of infections of the lower respiratory tract in this cohort. CRP evaluation allows to improve CAP diagnostics in patients with CHF and significantly reduce the number of antibacterial treatments without worsening outcomes.

REFERENCES:
  1. Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S. Community-acquired pneumonia in patients with chronic heart failure: clinical features and the diagnostic role of serum biomarkers. Pulmonologia, 2019,vol. 29, no. 4, pp. 391–402. (In Russ.)
  2. Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S., Mladov V.V. C-reactive protein evaluation in community-acquired pneumonia with comorbid chronic heart failure as criterion of antibiotic prescription. Kardiologia, vol. 59, no. 2 S, pp. 40–46. (In Russ.)
  3. Bobylev A.A., Rachina S.A., Avdeev S.N., Kozlov R.S., Sukhorukova M.V., Yatsyshchina S.B., Elkina M.A., Yudanova T.A. Etiology of community-acquired pneumonia in patients with chronic heart failure. Pulmonologia,2019, vol. 29, no. 3, pp. 293–301. (In Russ.)
  4. Bobylev A.A., Rachina S.A., Avdeev S.N., Mladov V.V. The prospects of biomarkers for the diagnostics of community-acquired pneumonia with comorbid chronic heart failure. Klinicheskaya farmakologia i terapia, 2018, vol. 27, no. 3, pp. 16–25. (In Russ.)
  5. Velkov V.V. C-reactive protein – structure, functions, evaluation methods, clinical significance. Laboratornayameditsina, 2006, no. 8, pp. 1–7. (In Russ.)
  6. Mareev V.Yu., Ageev F.T., Artyunov G.P., Koroteev A.V.,Mareev Yu.V., Ovchinnikov A.G., Belenkov Yu.N.,Vasyuk Yu.A., Galyavich A.S., Garganeeva A.A., Gilyarevsky S.R., Glezer M.G., Koziolova N.A., Koi Ya.I., Lopatin Yu.M., Martynov A.I., Moiseev V.S., Revishvili A.Sh., Sitnikova M.Yu., Skibitsky V.V., Sokolov E.I., Storozhakov G.I., Fomin I.V., Chesnikova A.I., Shlyakhto E.V. Russian Heart Failure Society, Russian Society of Cardiology, Russian Scientific Medical Society of Internal Medicine: The national recommendations on diagnosis and treatment of CHF (fourth revision). Serdechnaya Nedostatochnost, 2013, vol. 14, no. 7, pp. 379–472. (In Russ.)
  7. Khamitova A.F., Dozhdev S.S., Zagidullin Sh.Z., Ionin V.A., Gareeva D.F., Zagidullin N.Sh. The role of serum biomarkers for prognosing heart failure and lethality. Arterial’naya Gipertenziya, 2018, vol. 24, 1, pp. 101–107. (In Russ.)
  8. Chuchalin A.G., Sonopalnikov A.I., Kozlov R.S., Tyurin I.E., Rachina S.A. Community-acquired pneumonia in adults: practical recommendations on diagnosis, treatment and prevention (Doctor’s guidelines). Klinicheskaya mikrobiologia, antimikrobnaya khimioterapia, 2010, vol. 12, no. 3, pp. 186–225. (In Russ.)
  9. Albaum M.N., Hill L.C., Murphy M., Li Y.H., Fuhrman C.R., Britton C.A., Kapoor W.N., Fine M.J. Interobserver reliability of the chest radiograph in communityacquired pneumonia. PORT Investigators. Chest., 1996, vol. 110, no. 2, pp. 343–350.
  10. Bacci M.R., Leme R.C., Zing N.P., Murad N., Adami F., Hinnig P.F., Feder D., Chagas A.C., Fonseca F.L. IL-6 and TNF-αserum levels are associated with early death in community-acquired pneumonia patients. Braz. J. Med. Biol. Res., 2015, vol. 48, no. 5, pp. 427–432.
  11. Basi S.K., Marrie T.J., Huang J.Q., Majumdar S.R. Patients admitted to hospital with suspected pneumonia and normal chest radiography. epidemiology, microbiology and outcomes. Am. J. Med., 2004, vol. 117, no. 5, pp. 305–311.
  12. Boyd A.R., Orihuela C.J. Dysregulated inflammation as a risk factor for pneumonia in the elderly. Aging Dis., 2011, vol. 2, no. 6, pp. 487–500. 13. Brown J.S. Biomarkers and community-acquired pneumonia. Thorax., 2009, vol. 64, no. 7, pp. 556–558.
  13. Bruunsgaard H. The clinical impact of systemic lowlevel inflammation in elderly populations. With specialreference to cardiovascular disease, dementiaand mortality. Dan. Med. Bull., 2006, vol. 53, no. 3, 285–309.
  14. Calbo E., Alsina M., Rodríguez-Carballeira M., Lite J., Garau J. The impact of time on the systemic inflammatory response in pneumococcal pneumonia. Eur.Respir. J., 2010, vol. 35, no. 3, pp. 614–618.
  15. Crisafulli E., Menéndez R., Huerta A., Martinez R., Montull B., Clini E., Torres A. Systemic inflammatory pattern of patients with community-acquired pneumonia with and without COPD. Chest., 2013, vol. 143, 4, pp. 1009–1017.
  16. Dai S., Walsh P., Wielgosz A., Gurevich Y., Bancej C., Morrison H. Comorbidities and mortality associated with hospitalized heart failure in Canada. Can. J. Cardiol., 2012, vol. 28, no. 1, pp. 74–79.
  17. de Werra I., Jaccard C., Corradin S.B., Chioléro R., Yersin B., Gallati H., Assicot M., Bohuon C., Baumgartner J.D., Glauser M.P., Heumann D. Cytokines, nitrite/nitrate, soluble tumor necrosis factor receptors, and procalcitonin concentrations: comparisons in patients with septic shock, cardiogenic shock, and bacterial pneumonia Crit. Care. Med., 1997, vol. 25, no. 4, pp. 607–613.
  18. Derosa G., Maffioli P., Simental-Mendía L.E., Bo S., Sahebkar A. Effect of curcumin on circulating interleukin-6 concentrations: A systematic review and metaanalysis of randomized controlled trials. Pharmacol. Res., 2016, vol. 111, pp. 394–404.
  19. Dickstein K., Cohen-Solal A., Filippatos G., McMurray J.J., Ponikowski P., Poole-Wilson P.A., Strömberg A., van Veldhuisen D.J., Atar D., Hoes A.W., Keren A., Mebazaa A., Nieminen M., Priori S.G., Swedberg K. ESC guidelines for the diagnosis and treatment of acute and chronic heart failure the Task Force for the diagnosis and treatment of acute and chronic heart failure 2008 of the European Society of Cardiology. Developed in collaboration with the Heart Failure Association of the ESC (HFA) and endorsed by the European Society of Intensive Care Medicine (ESICM). Eur. J. Heart. Fail., 2008, vol. 10, no. 10, pp. 933–989.
  20. El-Solh A.A., Sikka P., Ramadan F., Davies J. Etiology of severe pneumonia in the very elderly. Am. J. Respir. Crit. Care. Med., 2001, vol. 163, no 3, pp. 645–651. 22. Fernández-Sabé N., Carratalà J., Rosón B., Dorca J., Verdaguer R., Manresa F., Gudiol F. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. Medicine (Baltimore)., 2003, vol. 82, no. 3, pp. 159–169.
  21. Fink A.M., Gonzalez R.C., Lisowski T., Pini M., Fantuzzi G., Levy W.C., Piano M.R. Fatigue, inflammation and projected mortality in heart failure. J. Card. Fail., 2012, vol. 18, no. 9, pp. 711–716.
  22. Fung H.B., Monteagudo-Chu M.O. Community-acquired pneumonia in the elderly. Am. J. Geriatr. Pharmacother., 2010, vol. 8, no. 1, pp. 47–62.
  23. Gau J.T., Acharya U., Khan S., Heh V., Mody L., Kao T.C. Pharmacotherapy and the risk for community-acquired pneumonia. BMC Geriatrics., 2010, vol. 10:45. doi: 10.1186/1471-2318-10-45
  24. Gilbert D.N. Procalcitonin as a biomarker in respiratory tract infection. Clin. Infect. Dis., 2011, vol. 52, 346–350.
  25. González-Castillo J., Martín-Sánchez F.J., Llinares P. Guidelines for the management of community-acquired pneumonia in the elderly patient. Rev. Esp. Quimioter., 2014, vol. 27, no. 1, pp. 69–86.
  26. Goyal A., Norton C.R., Thomas T.N., Davis R.L., Butler J., Ashok V., Zhao L., Vaccarino V., Wilson P.W. Predictors of incident heart failure in a large insured population: a one million person-year follow-up study. Circ. Heart Fail., 2010, vol. 3, no. 6, pp. 698–705.
  27. Gutiérrez F., Masiá M., Rodríguez J.C., Mirete C., Soldán B., Padilla S., Hernández I., De Ory F., Royo G., Hidalgo A.M. Epidemiology of community-acquired pneumonia at the dawn of the 21 st century: a pros pective study on the Mediterranean coast of Spain. Clin. Microbiol. Infect., 2005, vol. 11, no. 10, pp. 788–800.
  28. Horie M., Ugajin M., Suzuki M., Noguchi S., Tanaka W., Yoshihara H., Kawakami M., Kichikawa Y., Sakamoto Y. Diagnostic and prognostic value of procalcitonin in community-acquired pneumonia. Am. J. Med. Sci., 2012, vol. 343, no. 1, pp. 30–35.
  29. Ishiguro T., Takayanagi N., Yamaguchi S., Yamakawa H., Nakamoto K., Takaku Y., Miyahara Y., Kagiyama N., Kurashima K., Yanagisawa T., Sugita Y. Etiology and factors contributing to the severity and mortality of community-acquired pneumonia. Intern. Med., 2013, vol. 52, no. 3, pp. 317–324.
  30. Janssens J.P., Krause K.H. Pneumonia in the very old. Lancet. Infect. Dis., 2004, vol. 4, no. 2, pp. 112–124.
  31. Joffe E., Justo D., Mashav N., Swartzon M., Gur H., Berliner S., Paran Y. C-reactive protein to distinguish pneumonia from acute decompensated heart failure. Clin. Biochem., 2009, vol. 42, no. 16–17, pp. 1628–1634.
  32. José V., Domingo M.L., Soto C., Cogollos J. Radiology of bacterial pneumonia. Eur. J. Radiol., 2004, vol. 51, no. 2, pp. 102–113.
  33. Kafkas N., Venetsanou K., Patsilinakos S., Voudris V., Antonatos D., Kelesidis K., Baltopoulos G., Maniatis P., Cokkinos D.V. Procalcitonin in acute myocardial infarction. Acute. Card. Care., 2008, vol. 10, no. 1, pp. 30–36.
  34. Kanwar M., Brar N., Khatib R., Fakih M.G. Misdiagnosis of community-acquired pneumonia and inappropriate utilization of antibiotics: side effects of the 4‑h antibiotic administration rule. Chest., 2007, vol. 131, no. 6, pp. 1865–1869.
  35. Kaplan V., Angus D.C. Community-acquired pneumonia in the elderly. Crit. Care. Clin., 2003, vol. 19, no. 4, pp. 729–748.
  36. Kaplan V., Angus D.C., Griffin M.F., Clermont G., Scott Watson R., Linde-Zwirble W.T. Hospitalized community-acquired pneumonia in the elderly: Age- and sexrelated patterns of care and outcome in the United States. Am. J. Respir. Crit. Care. Med., 2002, vol. 165, no. 6, pp. 766–772.
  37. Kelly E., MacRedmond R.E., Cullen G., Greene C.M., McElvaney N.G., O’Neill S.J. Community-acquired pneumonia in older patients: does age influence systemic cytokine levels in community-acquired pneumonia? Respirology, 2009, vol. 14, no. 2, pp. 210–216.
  38. Kim J.H., Seo J.W., Mok J.H., Kim M.H., Cho W.H., Lee K., Kim K.U., Jeon D., Park H.K., Kim Y.S., Kim H.H., Lee M.K. Usefulness of plasma procalcitonin to predict severity in elderly patients with community-acquired pneumonia. Tuberc. Respir. Dis. (Seoul), 2013, vol. 74, no. 5, pp. 207–214.
  39. Kinugawa T., Kato M., Yamamoto K., Hisatome I., Nohara R. Proinflammatory cytokine activation is linked to apoptotic mediator, soluble Fas level in patients with chronic heart failure. Int. Heart. J., 2012, vol. 53, no. 3, pp. 182–186.
  40. Köktürk N., Kanbay A., Bukan N., Ekim N. The value of serum procalcitonin in differential diagnosis of pulmonary embolism and community-acquired pneumonia. Clin. Appl. Thromb. Hemost., 2011, vol. 18, no. 5, pp. 519–525.
  41. Krüger S., Welte T. Biomarkers in community-acquired pneumonia. Expert. Rev. Respir. Med., 2012, vol. 6, no. 2, pp. 203–214.
  42. Lecour S., James R.W. When are pro-inflammatory cytokines SAFE in heart failure? Eur. Heart. J., 2011, vol. 32, no. 6, pp. 680–685.
  43. Lee Y.J., Lee J., Park Y.S., Lee S.M., Yim J.J., Yoo C.G., Kim Y.W., Han S.K., Lee C.H. Predictors of cardiogenic and non-cardiogenic causes in cases with bilateral chest infiltrates. Tuberc. Respir. Dis. (Seoul)., 2013, vol. 74, no. 1, pp. 15–22.
  44. Loeb M.B., Carusone S.B., Marrie T.J., Brazil K., Krueger P., Lohfeld L., Simor A.E., Walter S.D. Interobserver reliability of radiologists’ interpretations of mobile chest radiographs for nursing home-acquired pneumonia. J. Am. Med. Dir. Assoc., 2006, vol. 7, no. 7, pp. 416–419.
  45. Maisel A., Neath S.X., Landsberg J., Mueller C., Nowak R.M., Peacock W.F., Ponikowski P., Möckel M., Hogan C., Wu A.H., Richards M., Clopton P., Filippatos G.S., Di Somma S., Anand I., Ng L.L., Daniels L.B., Christenson R.H., Potocki M., McCord J., Terracciano G., Hartmann O., Bergmann A., Morgenthaler N.G., Anker S.D. Use of procalcitonin for the diagnosis of pneumonia in patients presenting with a chief complaint of dyspnoea: results from the BACH (Biomarkers in Acute Heart Failure) trial. Eur. J. Heart. Fail., 2012, vol. 14, no. 3, pp. 278–286.
  46. Mannel D.N., Echtenacher B. TNF in the inflammatory response. Chem. Immunol., 2000, vol. 74, pp. 141–161.
  47. Maruyama T., Gabazza E.C., Morser J., Takagi T., D’Alessandro-Gabazza C., Hirohata S., Nakayama S., Ramirez A.Y., Fujiwara A., Naito M., Nishikubo K., Yuda H., Yoshida M., Takei Y., Taguchi O. Community-acquired pneumonia and nursing home-acquired pneumonia in the very elderly patients. Respir. Med., 2010, vol. 104, no. 4, pp. 584–592.
  48. Moon J., Kang S.M., Cho I.J., Oh J., Shim J., Lee S.H., Jang Y., Chung N. Clinical and echocardiographic findings of newly diagnosed acute decompensated heart failure in elderly patients. Yonsei. Med. J., 2011, vol. 52, no. 1, pp. 33–38.
  49. Mueller C., Scholer A., Laule-Kilian K., Martina B., Schindler C., Buser P., Pfisterer M., Perruchoud A.P. Use of B-type natriuretic peptide in the evaluation and management of acute dyspnea. N. Engl. J. Med., 2004, vol. 350, no. 7, pp. 647–654.
  50. Mueller T., Leitner I., Egger M., Haltmayer M., Dieplinger B. Association of the biomarkers soluble ST2, galectin-3 and growth-differentiation factor-15 with heart failure and other non-cardiac diseases. Clin.Chim. Acta., 2015, vol. 445, pp. 155–160.
  51. Pei Z.Y., Zhao Y.S., Li J.Y., Xue Q., Gao L., Wang S.W. Fifteen-year evolving trends of etiology and prognosis in hospitalized patients with heart failure. Zhonghua.Xin. Xue. Guan. Bing. Za. Zhi., 2011, vol. 39, 5, pp. 434–439.
  52. Peschel T., Schönauer M., Thiele H., Anker S.D., Schuler G., Niebauer J. Invasive assessment of bacterial en dotoxin and inflammatory cytokines in patients with acute heart failure. Eur. J. Heart Fail., 2003, vol. 5, 5, pp. 609–614.
  53. Quah J., Jiang B., Tan P.C., Siau C., Tan T.Y. Impact of microbial aetiology on mortality in severe communityacquired pneumonia. BMC. Infect. Dis., 2018, vol. 18, no. 1: 451. doi: 10.1186/s12879-018-3366-4
  54. Reinhart K., Karzai W., Meisner M. Procalcitonin as a marker of the systemic inflammatory response to infection. Intensive Care. Med., 2000, vol. 26, no. 9, pp. 1193–1200.
  55. Restrepo M.I., Reyes L.F. Pneumonia as a cardiovascular disease. Respirology., 2018, vol. 23, no. 3, 250–259.
  56. Saito A., Kohno S., Matsushima T., Watanabe A., Oizumi K., Yamaguchi K., Oda H. Prospective multicenter study of the causative organisms of community-acquired pneumonia in adults in Japan. J. Infect. Chemother., 2006, vol. 12, no. 2, pp. 63–69.
  57. Stanciu A.E., Vatasescu R.G., Stanciu M.M., Iorgulescu C., Vasile A.I., Dorobantu M. Cardiac resynchronization therapy in patients with chronic heart failure is associated with anti-inflammatory and anti-remodeling effects. Clin. Biochem., 2013, vol. 46, no. 3, pp. 230–234.
  58. Tanaka N., Matsumoto T., Kuramitsu T., Nakaki H., Ito K., Uchisako H., Miura G., Matsunaga N., Yamakawa K. High resolution CT findings in community-acquired pneumonia. J. Comput. Assist. Tomogr., 1996, vol. 20, no. 4, pp. 600–608.
  59. Viasus D., Garcia-Vidal C., Manresa F., Dorca J., Gudiol F., Carratalà J. Risk stratification and prognosis of acute cardiac events in hospitalized adults with community- acquired pneumonia. J. Infect., 2013, vol. 66, 1, pp. 27–33.
  60. Vila-Corcoles A., Ochoa-Gondar O., Rodriguez-Blanco T., Raga-Luria X., Gomez-Bertomeu F. Epidemiology of community-acquired pneumonia in older adults: A population-based study. Respir. Med., 2009, vol. 103, no. 2, pp. 309–316.
  61. Von Baum H., Welte T., Marre R., Suttorp N., Ewig S. Community-acquired pneumonia through Enterobacteriaceae and Pseudomonas aeruginosa: Diagnosis, incidence and predictors. Eur. Respir. J., 2010, vol. 35, no. 3, pp. 598–605.
  62. Wang W., Zhang X., Ge N., Liu J., Yuan H., Zhang P., Liu W., Wen D. Procalcitonin testing for diagnosis and short-term prognosis in bacterial infection complicated by congestive heart failure: a multicenter analysis of 4,698 cases. Crit. Care., 2014, vol. 18, no. 1: R4. doi: 10.1186/cc13181
  63. Wang Y., Zhou Y., Meng L., Lu X., Ou N., Li X. Inflammatory mediators in Chinese patients with congestive heart failure. J. Clin. Pharmacol., 2009, vol. 49, no. 5, pp. 591–599.
  64. Woods G.L., Isaacs R.D., McCarroll K.A., Friedland I.R. Ertapenem therapy for community-acquired pneumonia in the elderly. J. Am. Geriatr. Soc., 2003, vol. 51, no. 11, pp. 1526–1532.
  65. Xiao K., Su L.X., Han B.C., Yan P., Yuan N., Deng J., Li J., Xie L.X. Analysis of the severity and prognosis assessment of aged patients with community-acquired pneumonia: a retrospective study. J. Thorac. Dis., 2013, vol. 5, no. 5, pp. 626–633.
  66. Yoon J.Y., Yang D.H., Cho H.J., Kim N.K., Kim C.Y., Son J., Roh J.H., Jang S.Y., Bae M.H., Lee J.H., Park H.S., Cho Y., Chae S.C. Serum levels of carbohydrate antigen 125 in combination with N-terminal probrain natriuretic peptide in patients with acute decompensated heart failure. Korean. J. Intern. Med., 2019, vol. 34, no. 4, pp. 811–818.
  67. Zalacain R., Torres A., Celis R., Blanquer J., Aspa J., Esteban L., Menéndez R., Blanquer R., Borderías L. Community-acquired pneumonia in the elderly: Spanish multicentre study. Eur. Respir. J., 2003, vol. 21, no. 2,pp. 294–302.
KEYWORDS:

community-acquired pneumonia, chronic heart failure, diagnostics, chest multispiral computed tomography, C-reactive protein.

FOR CORRESPONDENCE:

Smolensk State Medical University

28, Krupskaya St., 214019, Smolensk, Russia

Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy

46‑a, Kirov St., 214019, Smolensk, Russia

Andrey A. Bobylev, Candidate of Medical Sciences, Researcher, Scientific Research Centre; Project Coordinator, IACMAC

Tel.: +7 (4812) 45-06-02

Е-mail: andbobylev@yandex.ru

Roman S. Kozlov, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy

of Sciences, President of IACMAC

Tel. +7 (4812) 55-02-75

Е-mail: roman.kozlov@antibiotic.ru

Peoples’ Friendship University of Russia

6, Miklukho-Maklaya St., 117198, Moscow, Russia

Svetlana A. Rachina, Doctor of Medical Sciences, Professor, Department of Internal Medicine with

the subspecialty of cardiology and functional diagnostics named after V.S. Moiseev

Tel.: +7 (495) 434-53-00

Е-mail: svetlana.ratchina@antibiotic.ru

I.M. Sechenov 1st Moscow State Medical University

15, Build. 2, Dovatora St., 119992, Moscow, Russia

Pulmonology Research Institute

28, Orekhovy boulevard, 105077, Moscow, Russia

Sergey N. Avdeev, Doctor of Medical Sciences, Professor, Corresponding Member of the Russian Academy of Sciences, Head of Pulmonology Department, I.M. Sechenov 1st Moscow State Medical University;

Head of Clinical Department, Pulmonology Research Institute

Tel.: +7 (495) 708-35-76

Е-mail: serg_avdeev@list.ru

HEPATOTOXIC REACTIONS OF TB PATIENTS TO MAJOR TB DRUGS. THE STATUS OF THE ISSUE

Article 3.Page 22.
ARTICLE TITLE:

HEPATOTOXIC REACTIONS OF TB PATIENTS TO MAJOR TB DRUGS. THE STATUS OF THE ISSUE

DOI: 10.7868/S258766782002003X

AUTORS:

Averbakh М.М.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 10.01.2020

The review provides the latest data on morphology, laboratory diagnostics, some inherited metabolic disorders

and immunopathological responses associated with hepatotoxic reactions to treatment with isoniazid, rifampicin or pyrazinamide. Reactions to isoniazid are more often preconditioned by genetic defects in N-acetyltransferase 2 (NAT2) or cytochrome P450 CYP2 E1 c1/c1 allele, while reactions to rifampicin are preconditioned by defects in cytochrome P450 (CYP3 A4). For pyrazinamide, reliable data on possible genetic defects are not available yet. We provide the data on studies of various laboratory parameters of enzymes as potential new markers of hepatotoxic reactions. We also analyze the studies of immunological diagnostics involving blast-transformation reaction or cytokine determination for the confirmation of hepatotoxic reactions to isoniazid, rifampicin, pyrazinamide or ethambutol.

The study was conducted in the framework of the scientific research no. 0515-2019-0016 “Personalized approaches to pulmonary TB treatment in children and adolescents”.

REFERENCES:
  1. Dubrovskaya N.A. Clinical and immunological presentations of rifampicin-induced adverse reactions in TB treatment. Thesis for a candidate’s degree in medicine. Moscow, 1984. (In Russ.)
  2. Nikitin I.G., Storozhakov G.I., Bueverov A.O. Drug-induced liver injury. In: Liver and biliary tract diseases. Ed. by V.T. Ivashkin. Moscow, M-Vesti, 2005, pp. 217–223. (In Russ.)
  3. Panova L.V. Hepatotoxic reactions to chemotherapy and their correction in adolescents with TB. Abstract of thesis for a doctor’s degree. Moscow, 2001. (In Russ.)
  4. Abbara A., Chitty S., Roe J.K., Ghani R., Collin S.M., Ritchie A., Kon O.M., Dzvova J., Davidson H., Edwards T.E., Hateley C., Routledge M., Buckley J., Davidson R.N., John L. Drug-induced liver injury from antituberculous treatment: a retrospective study from a large TB centre in the UK. BMC Infectious Diseases, 2017, vol. 17, p. 231, doi: 10.1186/s12879-017-2330‑z 5. Aithal G.P., Watkins P.B., Andrade R.J., Larrey D., Molokhia M., Takikawa H., Hunt C.M., Wilke R.A., Avigan M., Kaplowitz N., Bjornsson E., Daly A.K. Case definition and phenotype standardization in druginduced liver injury. Clin. Pharmacol. Ther., 2011, vol. 89, pp. 806–815, doi.org/10.1038/clpt.2011.58
  5. Attri S., Rana S.V., Vaiphei K., Sodhi C.P., Katyal R., Goel R.C., Nain CK, Singh K. Isoniazid- and rifampicin-induced oxidative hepatic injury –protection by N-acetylcysteine. Hum. Exp. Toxicol., 2000, vol. 19,pp. 517–522, doi:10.1191/096032700674230830 7. Cao J., Yijun Mi.Y., Shi C., Bian Y., Huang C., Ye Z., Liu L., Miao L. First-line anti-tuberculosis drugs induce hepatotoxicity: A novel mechanism based on a urinary metabolomics platform. Biochemical and Biophysical Research Communications, doi: 10.1016/j.bbrc.2018.02.030
  6. Chowdhury A., Santra A., Kundu S., Mukherjee A., Pandit A., Chaudhuri S., Dhali G.K. Induction of oxidative stress in antitubercular drug-induced hepatotoxicity. Indian J. Gastroenterol., 2001, vol. 20,pp. 97–100. PMID:11400818.
  7. Coombs P.R., Gell P.G. Classification of allergic reactions responsible for clinical hypersensitivity and disease. In: Clinical aspects of immunology. Ed. By R.R Gell. Oxford, Oxford University Press, 1968, pp. 575–596.
  8. Ji G.J., Wang Y., Wu S.Q., Liu Q.Q., Wu J.C., Zhang M.M., Sandford A.J., He J.Q. Association between TXNRD1 polymorphisms and anti-tuberculosis drug-induced hepatotoxicity in a prospective study. Genet. Mol. Res., 2016, vol. 2, p. 15, doi: 10.4238/gmr.15038296
  9. Kolars J.C., Schmiedlin-Ren P., Schuetz J.D., Fang C., Watkins P.B. Identification of rifampin-inducible P450 IIIA4 (CYP3 A4) in human small bowel enterocytes. J. Clin. Invest., 1992, vol. 90, pp. 1871–1878, doi: 10.1172/JCI116064
  10. Leise M.D., Poterucha J.J., Talwalkar J.A. Drug-Induced Liver Injury. Mayo. Clin. Proc., 2014, vol. 89, 95–106, doi: org/10.1016/j.mayocp.2013.09.016
  11. Li C., Long J., Hu X., Zhou Y. GSTM1 and GSTT1 genetic polymorphisms and risk of anti-tuberculosis drug-induced hepatotoxicity: an updated meta-analysis. Eur. J. Clin. Microbiol. Infect. Dis., 2013, vol. 32, 859–868, doi: 10.1007/s10096-013-1831‑y
  12. Licata A. Adverse drug reactions and organ damage: The liver. Eur. J. Intern. Med., 2016, doi: org/10.1016/j.ejim.2015.12.017
  13. Lochmatter P., Zawodniak A., Pichler W.J. In vitro tests in drug hypersensitivity diagnosis. Immunol. Allergy Clin. N. Am., 2009, vol. 29, pp. 537–554. doi: 10.1016/j.iac.2009.04.009
  14. Maria V.A.J., Victorino R.M.M. Diagnostic value of specific T cell reactivity to drugs in 95 cases of drug induced liver injury. Gut., 1997, vol. 41, pp. 534–540, doi: 10.1136/gut.41.4.534
  15. Metushi I.G., Cai P., Zhu X., Nakagawa T., Uetrecht J.P. A fresh look at the mechanism of isoniazid-induced hepatotoxicity. Clin. Pharmacol. Ther., 2011, vol. 89, pp. 911–914, doi: 10.1038/clpt.2010.355
  16. Metushi I.G., Zhu X., Chen X., Gardam M.A. and Uetrecht J. Mild isoniazid-induced liver injury in humans is associated with an increase in Th17 cells and T cells producing IL-10. Chem. Res. Toxicol. 2014, vol. 27, pp. 683–689, doi: 10.1021/tx500013z
  17. Mikus M., Drobin K., Gry M., Bachmann J., Lindberg J., Yimer G., Aklillu E., Makonnen E., Aderaye G., Roach J., Fier I., Kampf C., Gеopfert J., Perazzo H., Poynard T., Stephens C., Andrade R.J., Lucena M.I., Arber N., Uhlen M., Watkins P.B., Schwenk J.M., Nilsson P., Schuppe-Koistinen I. Elevated levels of circulating CDH5 and FABP1 in association with human drug-induced liver injury. Liver International, 2016, doi: 10.1111/liv.13174
  18. Nishimura Y., Kurata N., Sakurai E., Yasuhara H. Inhibitory effect of antituberculosis drugs on human cytochrome P450‑mediated activities. J. Pharmacol. Sci., 2004, vol. 96, pp. 293–300, doi: 10.1254/jphs.fp0040296
  19. Ogese M.O., Faulkner L., Jenkins R.E., French N.S., Copple I.M., Antoine D.J., Elmasry M., Malik H., Goldring C.E., Park B.K., Betts C.J., Naisbitt D.J. Characterization of drug-specific signalling between primary human hepatocytes and immune cells. ToxicologicalSciences, 2017, pp. 1–14, doi: 10.1093/toxsci/kfx069
  20. Pichler W.J., Tilch J. The lymphocyte transformation test in the diagnosis of drug hypersensitivity. Allergy, 2004, vol. 59, pp. 809–820, doi: 10.1111/j.1398-9995.2004.00547.x
  21. Sarma G.R., Immanuel C., Kailasam S., Narayana A.S., Venkatesan P. Rifampin-induced release of hydrazine from isoniazid. A possible cause of hepatitis during treatment of tuberculosis with regimens containing isoniazid and rifampin. Am. Rev. Respir. Dis., 1986, vol. 133, pp. 1072–1075, doi: 10.1164/arrd.1986.133.6.1072
  22. Schomaker S., Warner R., Bock J., Johnson K., Potter D., Van Winkle L., Aubrecht J. Assessment of emerging biomarkers of liver injury in human subjects. Toxicological sciences, 2013, vol. 132, pp. 276–283, doi: 10.1093/toxsci/kft009
  23. Sodhi C.P., Rana S.V., Mehta S.K., Vaiphei K., Attari S., Mehta S. Study of oxidative-stress in isoniazid-rifampicin induced hepatic injury in young rats. Drug Chem. Toxicol., 1997, vol. 20, pp. 255–269, doi: 10.3109/01480549709003881
  24. Sun Q., Sha W., Gui X-W., Xiao Y-J., Zeng W-H., Sun W-W., Xiao H-P., Ye W-Y. Drug-induced lymphocyte stimulation test in the prediction of drug induced hypersensitivity to antituberculosis drugs. Diagn. Microbiol. Infect. Dis., 2015, doi: 10.1016/j.diagmicrobio.2015.03.008
  25. Suzuki Y., Miwa S., Shirai M., Ohba H., Murakami M., Fujita K. Suda T., Nakamura H., Hayakawa H., Chida K. Drug lymphocyte stimulation test in the diagnosis of adverse reactions to antituberculosis drugs. Chest, 2008, vol. 134, pp. 1027–1032, doi: 10.1378/chest.07-3088
  26. Te Brake L.H.M., de Knegt G.J., de Steenwinkel J.E., van Dam T.J.P., Burger D.M., Russel F.G.M., van Crevel R., Koenderink J.B., Aarnoutse R.E. The role of efflux pumps in tuberculosis treatment and their promise as a target in drug development: Unraveling the black box. Annu. Rev. Pharmacol. Toxicol., 2018, vol. 6, рр. 271–291, doi: 10.1146/annurev-pharmtox-010617-052438
  27. Tostmann A., Boeree M.J., Aarnoutse R.E., de Lange W.C.M., van der Ven A.J.A.M., Dekhuijzen R. Antituberculosis drug-induced hepatotoxicity: Concise up-to-date review. Journal of Gastroenterology and Hepatology, 2008, vol. 23, pp. 192–202, doi: 10.1111/j.1440-1746.2007.05207x
  28. Umeki S. Adverse effects of antitubercular drugs and significance of measurement of the drug-stimulating lymphocyte transformation rate. Jpn. J. Med., 1989, vol. 28, no. 3, pp. 335–340, doi: 10.2169/internalmedicine1962.28.335
  29. Usui T., Whitaker P., Meng X., Watson J., Antoine D.J., French N.S., Park B,K., Naisbitt D.J. Detection of drug-responsive T‑lymphocytes in a case of fatal antituberculosis drug-related liver injury. Chem. Res. Toxicol., 2016, vol. 29, pp. 1793–1795, doi: 10.1021/acs. chemrestox.6 b00393
  30. Usui T., Meng X., Saide K., Farrell J., Thomson P., Whitaker P., Watson J., French N.S., Park B.K., Naisbitt D.J. From the Cover: Characterization of isoniazid-specific T-cell clones in patients with anti-tuberculosis drug-related liver and skin injury. Toxicol. Sci.,2017, vol. 155, pp. 420–431, doi: 10.1093/toxsci/kfw218
  31. Walubo A., Smith P., Folb P.I. The role of oxygen free radicals in isoniazid-induced hepatotoxicity. MethodsFind. Exp. Clin. Pharmacol., 1998, vol. 20, pp. 649–655, doi: 10.1358/mf.1998.20.8.487491
KEYWORDS:

TB drugs, hepatotoxic reactions.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Mikhail M. Averbakh, Doctor of Medical Sciences, Professor, Principal Researcher, Immunology Department

Central TB Research Institute, Moscow, Russia

Tel.: +7 (499) 785-90-72

Е-mail: amm50@mail.ru

EXTRACTION OF Mycobacterium tuberculosis AFTER IN VIVO PHAGOCYTOSIS BY NEUTROPHILS FOR FU RTHER GENETIC AND FUNCTIONAL ANALYSES

Article  4.Page 30.
ARTICLE TITLE:

EXTRACTION OF Mycobacterium tuberculosis AFTER IN VIVO PHAGOCYTOSIS BY NEUTROPHILS FOR FU RTHER GENETIC AND FUNCTIONAL ANALYSES

DOI: 10.7868/S2587667820020041

AUTORS:

Majorov K.B.1, Grigorov A.S.2, Kondratieva E.V.1, Azhikina T.L.2, Apt A.S.1

1 Central TB Research Institute, Moscow, Russia

2 Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 29.01.2020

We developed a novel approach for ex vivo extraction of neutrophils containing high amounts of engulfed Mycobacterium tuberculosis. This the Percoll gradient-based method allows isolation of a pure mycobacterial population experienced phagocytosis during 2‑h interaction with neutrophils in vivo. We obtained the first set of RNA-seq data concerning the whole genome shifts in gene expression in these bacteria compared to the population developed in Dubos liquid medium. Our results indicate a very rapid mycobacterial adaptation to stressful conditions inside host phagocytes achieved by upregulation of genes involved in switch of oxidative metabolism and down-regulation of genes encoding virulence factors.

The research was conducted under financial support of the Russian Foundation of Basic Research (grant no. 19-04-00058).

REFERENCES:
  1. Azhikina1. T.L. Skvortsov T., Radaeva T., Mardanov A., Ravin N., Apt A., Sverdlov E. A new technique for obtaining whole pathogen transcriptomes from infected host tissues. Biotechniques, 2010, vol. 48, no. 2, pp. 139–144.
  2. Chin A.C., Parkos C.A. Neutrophil trans-epithelial migration and epithelial barrier function in IBD: potential targets for inhibiting neutrophil trafficking. Ann. N.Y. Acad. Sci., 2006, vol. 1072, pp. 276–287.
  3. Dallenga T., Repnik U., Corleis B., Eich J., Reimer R., Griffiths G.W., Schaible U.E.M. Tuberculosis-induced necrosis of infected neutrophils promotes bacterial growth following phagocytosis by macrophages. Cell Host & Microbe, 2017, vol. 22, no. 4, pp. 519–530.
  4. Eruslanov E.B., Lyadova I.V., Kondratieva T.K., Majorov K.B., Scheglov I.V., Orlova M.O., Apt A.S. Neutrophil responses to Mycobacterium tuberculosis infection in genetically susceptible and resistant mice. Infect. Immun., 2005, vol. 73, no. 3, pp. 1744–1753.
  5. Eum S.Y., Kong J.H., Hong M.S., Lee Y.J., Kim J.H., Hwang S.H., Cho S.N., Via L.E., Barry C.E. 3rd. Neutrophils are the predominant infected phagocytic cells in the airways of patients with active pulmonary
  6. Chest, 2010, vol. 137, no. 1, pp. 122–128.
  7. Jaeger B.N., Donadieu J., Cognet C. Bernat C., Ordoñez-Rueda D., Barlogis V., Mahlaoui N., Fenis A., Narni-Mancinelli E., Beaupain B., Bellanné-Chantelot C., Bajénoff M., Malissen B., Malissen M., Vivier E., Ugolini S. Neutrophil depletion impairs natural killer cell maturation, function and homeostasis. J. Exp. Med., 2012, vol. 209, no. 3, pp. 565–580.
  8. Ignatov D.V., Salina E.G., Fursov M.V., Skvortsov T.A., Azhikina T.L., Kaprelyants A.S. Dormant non-culturable Mycobacterium tuberculosis retains stable low-abundant mRNA. BMC Genomics, 2015, vol. 16, 954.
  9. Kondratieva T.K., Rubakova E.I., Linge I.A., Evstifeev V.V., Majorov K.B., Apt A.S. B cells delay neutrophil migration toward the site of stimulus: tardiness critical for effective bacillus Calmette-Guérin vaccination against tuberculosis infection in mice. J. Immunol., 2010, vol. 184, no. 3, pp. 1227–1234.
  10. Kozakiewicz L., Chen Y., Xu J., Wang Y., Dunussi-Joannopoulos K., Ou Q., Flynn J.L., Porcelli S.A., Jacobs W.R. Jr, Chan J. B cells regulate neutrophilia during Mycobacterium tuberculosis infection and BCG vaccination by modulating the intereleukine-17 response. PLoS Pathog., 2013, vol. 9, p. e1003472.
  11. Kuijpers T.W., van den Berg T.K., Roos D. Neutrophils forever…, Phagocyte-pathogen interactions. Ed: Russel D.G., Gordon S., ASM Press, Washington DC, 2009, pp. 3–26.
  12. Langmead B., Salzberg, S.L. Fast gapped-read alignment with Bowtie 2. Nat. Methods, 2012, vol. 9, 4, pp. 357–359.
  13. Lew J.M., Kapopoulou A., Jones L.M., Cole S.T. TubercuList – 10 years after. Tuberculosis (Edinb), 2011, vol. 91, no. 1, pp. 1–7.
  14. Nandi B., Behar S.M. Regulation of neutrophils by interferon-γlimits lung inflammation during tuberculosis infection. J. Exp. Med., 2012, vol. 208, no. 11, pp. 2251–2262.
  15. Nathan C. Neutrophils and immunity: challenges and opportunities. Nat. Rev. Immunol., 2006, vol. 6, no. 3, pp. 173–182.
  16. Quint J.K., Wedzicha J.A. The neutrophil in chronic obstructive pulmonary disease. J. Allergy Clin. Immunol., 2007, vol. 119, no. 5, pp. 1065–1071.
  17. Robinson M.D., McCarthy D.J., Smyth G.K. edgeR: a Bioconductor package for differential expression analysis of digital gene expression data. Bioinformatics, 2010, vol. 26, no. 1, pp. 139–140.
  18. Rohde K.H. Veiga D.F., Caldwell S., Balázsi G., Russell D.G. Linking the transcriptional profiles and the physiological states of Mycobacterium tuberculosis during an extended intracellular infection. PLoS Pathog., 2012, vol. 8, no. 6, p. e1002769.
  19. Tan S., Russell D. GTrans-species communication in the Mycobacterium tuberculosis-infected macrophage. Immunol. Rev., 2015, vol. 264, no. 1, pp. 233–248.
  20. Tanaka D., Kagari T., Doi H., Shimozato T. Essential role of neutrophils in anti-type II collagen antibody and lipopolysaccharide-induced arthritis. Immunology, 2006, vol. 119, no. 2, pp. 195–202.
  21. Wattam A.R., Abraham D., Dalay O., Disz T.L., Driscoll T., Gabbard J.L., Gough R., Hix D., Kenyon R., Machi D., Mao C., Nordberg E.K., Olson R., Overbeek R., Pusch G.D., Shukla M., Schulman J., Stevens R.L., Sullivan D.E., Vonstein V., Warren A., Will R., Wilson M.J., Yoo H.S., Zhang C., Zhang Y., Sobral B.W. PATRIC, the bacterial bioinformatics database and analysis resource. Nucleic Acids Res., 2014, vol. 42 (Database issue), pp. D581–591.
  22. Wells R.M., Jones C.M., Xi Z., Speer A., Danilchanka O., Doornbos K.S., Sun P., Wu F., Tian C., Niederweis M. Discovery of a siderophore export system essential for virulence of Mycobacterium tuberculosis. PLoS Pathog., 2013, vol. 9, no. 1, p. e1003120.
  23. Witko-Sarsat V., Rieu P., Descamps-Latscha B., Lesavre P., Halbwachs-Mecarelli L. Neutrophils: molecules, functions and pathophysiological aspects. Lab. Invest., 2000, vol. 80, no. 5, pp. 617–653.
  24. Yeremeev V., Linge I., Kondratieva T., Apt A. Neutrophils exacerbate tuberculosis infection in genetically susceptible mice. Tuberculosis (Edinb)., 2015, vol. 95, no. 4, pp. 447–451.
  25. Young M.D., Wakefield M.J., Smyth G.K., Oshlack A. Gene ontology analysis for RNA-seq: accounting for selection bias. Genome Biol. 2010, vol. 11, p. R14.
  26. Yu E.A., John S.H., Tablante E.C., King C.A., Kenneth J., Russell D.G., Mehta S. Host transcriptional responses following ex vivo re-challenge with Mycobacterium tuberculosis vary with disease status. PLoS One, 2017, vol. 12, no. 10, p. e0185640.
KEYWORDS:

mycobacteria, neutrophils, phagocytosis, gene expression, metabolism, virulence.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Konstantin B. Majorov, Candidate of Biological Sciences, Senior Researcher, Immunogenetics Laboratory,

Department of Immunology

Теl.: +7 (499) 785-90-72

E-mail: majorov@list.ru

Elena V. Kondratieva, Candidate of Biological Sciences, Senior Researcher, Immunogenetics Laboratory,

Department of Immunology

Теl.: +7 (499) 785-90-72

E-mail: alyonakondratyeva74@gmail.com

Alexander S. Apt, Doctor of Biological Sciences, Professor, Head, Immunogenetics Laboratory,

Department of Immunology

Теl.: +7 (499) 785-90-72

E-mail: alexapt0151@gmail.com

Shemyakin and Ovchinnikov Institute of Bioorganic Chemistry

16/10, Miklukho-Maklaya St., 117997, Moscow, Russia

Artem S. Grigorov, Postgraduate, Laboratory of Regulatory Transcriptomics

Tel.: +7 (495) 330-69-92

E-mail: artgrigorov@gmail.com

Tatyana L. Azhikina, Doctor of Biological Sciences, Head, Laboratory of Regulatory Transcriptomics

Tel.: +7 (495) 330-69-92

E-mail: tatazhik@ibch.ru

THE PECULIARITIES OF EXACERBATIONS.IN PATIENTS WITH.DI FFERENT CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHENOT YPES

Article 5.Page 36.
ARTICLE TITLE:

THE PECULIARITIES OF EXACERBATIONS.IN PATIENTS WITH.DI FFERENT CHRONIC OBSTRUCTIVE PULMONARY DISEASE PHENOT YPES

DOI: 10.7868/S2587667820020053

AUTORS:

Kudryavtseva E.Z.1, Makaryants N.N.2, Nikitina L.Yu.3

1 City Clinical Hospital No. 16, Kazan, Russia

2 Central TB Research Institute, Moscow, Russia

3“Medsi group” JSC, Clinical Diagnostic Centre “Medsi na Belorusskoi”, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 28.02.2020

We characterized the peculiarities of stable course and exacerbations in 140 patients with different chronic obstructive pulmonary disease (COPD) phenotypes. We analyzed the impact of the key treatment and diagnosis factors: comorbidities, choice of basic drugs, adequacy of inhaler techniques, polypragmasy. The personalized choice of treatment was crucial and allowed to improve outcomes and quality of life in patients with COPD.

REFERENCES:
  1. Avdeev S.N. Is it possible to improve outcomes in chronic obstructive pulmonary disease patients? Pulmonologia, 2015, vol. 25, no. 4, pp. 469–476. (In Russ.)
  2. Avdeev S.N. The role of exacerbations in COPD patients. Effeckivnaya farmakoterapia, 2014, vol. 29, 36–41. (In Russ.)
  3. Avdeev S.N. The strategies for prevention of chronic obstructive pulmonary disease exacerbations. Doktor.Ru, 2017, no. 10 (139), pp. 10–48. (In Russ.)
  4. Avdeev S.N. Chronic obstructive pulmonary disease phenotypes: the peculiarities of treatment. Consilium Medicum. Bolezni organov dykhania (Suppl.), 2010, no. 1, pp. 23–26. (In Russ.)
  5. Aisanov Z.R., Kalmanova E.N., Stulova O.Yu. The chronic obstructive pulmonary disease phenotype with frequent exacerbations and the modern anti-inflammatory therapy. Pulmonologia, 2013, no. 1, pp. 68–76. (In Russ.)
  6. Arkhipov V.V. Drug delivery routes for patients with chronic obstructive pulmonary disease. Prakticheskaya pulmonologia, 2019, no. 2, pp. 12–17. (In Russ.)
  7. Arkhipov V.V., Arkhipova D.E., Stukalina E.Yu., Lazarev A.A. The frequency of some chronic obstructive pulmonary disease phenotypes in the Russian Federation, characteristics and approaches to treatment. Prakticheskaya pulmonologia, 2016, no. 3, pp. 20–25. (In Russ.)
  8. Dvoretsky L.I. An elderly COPD patient: the strategy and the tactics of broncholytic therapy. Prakticheskaya pulmonologia, 2006, no. 4. (In Russ.)
  9. Karnaushkina M.A., Fedosenko S.V., Sazonov A.E., Petrov V.A., Vakolyuk R.M., Dvoretsky L.I., Ogorodova L.M. Difficulty of COPD predicting as a challenge to modern clinical pulmonology. Arkhiv vnutrennei meditsiny, 2016, no. 4 (30). (In Russ.)
  10. Leshcnenko I.V., Baranova I.I. The biomarkers of inflammation in chronic obstructive pulmonary disease. Pulmonologia, 2012, vol. 22, no. 2, pp. 108–117. (In Russ.)
  11. Ovcharenko S.I. Chronic obstructive pulmonary disease phenotypes and the ECLIPSE study: the first results. Pulmonologia, 2011, no. 3, pp. 113–117. (In Russ.)
  12. Sychev D.A. Polypragmasy in clinical practice: problems and solutions. In: Manual for physicians. Ed. by D.A. Sychev, V.A. Otdelenov. St. Petersburg, Professia, 2016, 224 p. (In Russ.)
  13. Prevention of acute exacerbations of COPD: American College of Chest Physicians and Canadian Thoracic Society Guidelines (Part 2). Pulmonologia, 2016,no. 26 (3), pp. 267–291. (In Russ.)
  14. Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevsky A.S., Leshchenko I.V., Meshcheryakova N.N., Ovcharenko S.I., Shmelev E.I. The Russian Respiratory Society federal clinical recommendations on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologia, 2014, no. 3, pp. 15–54. (In Russ.)
  15. Bosnic-Anticevich S.Z. Inhaler device handling: have we really started to address the problem? Eur. Respir. J., 2017, no. 49, 1700120. 
  16. Burrows B., Bloom J.W., Traver G.A. et al. The course and prognosis of different forms of chronic airways obstruction in a sample from the general population. N. Eng. J. Med., 1987, vol. 317, pp. 1309–1314.
  17. Brightling C.E. Chronic obstructive pulmonary disease phenotypes, biomarkers, and prognostic indicators. Allergy Asthma Proc., 2016, vol. 37, pp. 432–438.
  18. Crompton G.K., Barnes P.J., Broeders M. et al. The need to improve inhalation technique in Europe: a report by the Aerosol Drug Management Improvement Team. Respir. Med., 2006, vol. 100, pp. 1479–1494.
  19. Donaldson G.C., Seemungal T.A., Bhowmilk A. et al. Relationship between exacerbation frequency and lung function decline in chronic obstructive pulmonary disease. Thorax, 2002, vol. 57, pp. 847–852.
  20. Garcia-Aymerich J., Agusti А., BarberаJ.A. et al. Phenotypic  heterogeneity of chronic obstructive pulmonary disease. Arch. Bronconeumol., 2009, vol. 45, pp. 133–142.
  21. Global initiative for chronic obstructive lung disease. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. Revised 2017. [Electronic resource]. Mode of access: www.goldcopd.com (date of referral: 19.04.18).
  22. Goris S., Tasci S., Elmali F. The effects of training on inhaler technique and quality of life in patients with COPD. J. Aerosol. Med. Pulm. Drug. Deliv., 2013, vol. 26, pp. 336–344.
  23. Han M.K., Agusti A., Calverley P.M. et al. Chronic obstructive pulmonary disease phenotypes: The future of COPD. Am. J. Respir. Crit. Care Med., 2010, vol. 182, pp. 598–604.
  24. Hurst J.R., Vestbo J., Anzueto A. et al. Susceptibility to exacerbation in chronic obstructive pulmonary disease. N. Engl. J. Med. 2010, vol. 363, pp. 1128–1138.
  25. Price D.B. et al. Inhaler Errors in the CRITIKAL Study: Type, frequency, and association with asthma outcomes. The Journal of Allergy and Clinical Immunology: In Practice, 2017, vol. 5, pp. 1071–1081.
  26. Jalota L., Jain V.V. Action plans for COPD: strategies to manage exacerbations and improve outcomes. Int. J. Chron. Obstruct. Pulmon. Dis., 2016, vol. 11, pp. 1179–1188. doi:10.2147/COPD.S76970
  27. Menezes A.M., Montes de Oca M., Perez-Padilla R. et al. Increased risk of exacerbation and hospitalization in subjects with an overlap phenotype: COPDasthma. Chest, 2014, vol. 145 (2), pp. 297–304.
  28. Miravitlles M., Ferrer M., Pont A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. A 2 year follow-up study. Thorax, 2004, vol. 59, pp. 387–395.
  29. Miravitlles M., Guerrero T., Mayordomo C. et al. Factors associated with increased risk of exacerbation and hospital admission in a cohort of ambulatory COPD patients: a multiple logistic regression analysis. Respiration, 2000, vol. 67, pp. 495–501.
  30. Molimard M., Raherison C., Lignot S. et al. Chronic obstructive pulmonary disease exacerbation and inhaler device handling: real-life assessment of 2935 patients. Eur. Respir. J., 2017, vol. 49, pp. 1601–1794.
  31. Roversi S., Hawkins N.M. Time to move from prognostication to diagnosis and treatment of heart disease in acute exacerbation of COPD. Eur. Respir. J., 2017, vol. 49, pp. 1700–1912.
  32. Seemungal T.A.R., Donaldson G.C., Paul E.A. et al. Effect of exacerbation on quality of life in patients with chronic obstructive pulmonary disease. Am. J. Respir.Crit. Care. Med., 1998, vol. 157, pp. 1418–1422.
  33. Sundh J., Johansson G., Larsson K. et al. The phenotype of concurrent chronic bronchitis and frequent exacerbations in patients with severe COPD attending Swedish secondary care units. Int. J. Chron. Obstruct. Pulmon. Dis., 2015, vol. 10, pp. 2327–2334.
  34. Yawn B.P., Li Y., Tian H., Zhang J., Arcona S., Kahler K.H. Inhaled corticosteroid use in patients with chronic obstructive pulmonary disease and the risk of pneumonia: a retrospective claims data analysis. Int. J. Chron. Obstruct. Pulmon. Dis., 2013, vol. 8, pp. 295–304.
KEYWORDS:

chronic obstructive pulmonary disease (COPD), disease phenotype, treatment, polypragmasy, inhaler technique.

FOR CORRESPONDENCE:

City Clinical Hospital No. 16

121, Gagarin St., 420039, Kazan, Russia

Elvira Z. Kudryavtseva, Head Department of Pulmonology, pulmonologist

Tel.: +7 (917) 269-68-88

Е-mail: elk-a@inbox.ru

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Natalia N. Makaryants, Doctor of Medical Sciences, Leading Researcher, Department of Differential Diagnosis of Pulmonary TB and Extracorporal Treatments

Tel.: +7 (499) 785-91-56

Е-mail: roman4000@yandex.ru

≪Medsi group≫ JSC, Clinical Diagnostic Centre “Medsi na Belorusskoi”

3A, Gruzinsky per., 123056, Moscow, Russia

Lidiya Yu. Nikitina, Doctor of Medical Sciences, Physician

Tel.: +7 (908) 882-86-20

Е-mail: lidiya_nikitina@mail.ru

SURGICAL TREATMENT OF BRONCHOPLEURAL COMPLICATIONS AFTER PNEUMONECTOMY.IN PATIENTS WITH TUBERCULOSIS

Article 6.Page 49.
ARTICLE TITLE:

SURGICAL TREATMENT OF BRONCHOPLEURAL COMPLICATIONS AFTER PNEUMONECTOMY.IN PATIENTS WITH TUBERCULOSIS

DOI: 10.7868/S2587667820020065

AUTORS:

Giller D.B.1, Kesaev O.Sh.1, Ergeshov A.E.2, Koroyev V .V.1, Glotov A.A.1, Gadzhieva P .G.1, Glotov E.M.1, Imagozhev Ya.G.3, Pekhtusov V .A.4, Nematov O.N.5

1 I.M. Sechenov 1st Moscow State Medical University, Moscow, Russia

2 Central TB Research Institute, Moscow, Russia

3 Ingush State University, Nazran, Russia

4 Tambov Oblast TB Dispensary, Tambov oblast, Russia

5 Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology, Tashkent, Uzbekistan

DESCRIPTION OF ARTICLE:

Submitted as of 12.03.2020

The aim of our study was to increase the effectiveness of surgical treatment of bronchopleural complications after pneumonectomy in patients with tuberculosis based on modern indications, tactics, techniques and methods of postoperative management.

Materials and methods. We analyzed case histories of 114 patients, who underwent different surgical interventions for postpneumonectomy bronchopleural complications at Central TB Research Institute in 2004–2010 and I.M. Sechenov 1st Moscow State Medical University Hospital in 2011–2017. The patients were divided in two groups for better assessment of outcomes: group 1 – patients with empyema and bronchial fistula, group 2 – patients with empyema without bronchial fistula.

Results. In group 1 surgical treatment resulted in empyema healing and bronchial fistula closure in 57 (86.4%) patients, hospital mortality was 9% (6 patients); in group 2 postpneumonectomy empyema was cured in all patients, none of patients died. Thus, the total effectiveness of treatment was 92.1%.

Conclusion. The development of bronchopleural complications after pneumonectomy is a difficult clinical situation, which requires complex, often multistage surgical interventions. However, the use of the recommended surgery tactics and techniques allows to achieve high effectiveness along with low relapse or mortality rates.

REFERENCES:
  1. Bazhenov A.V., Kholny P.M., Kardapoltsev L.V., Tsvirenko A.S., Basyrov R.T., Motus I.Ya. The experience of treatment for right main bronchial stump fistula using vascular occluder. Tuberculosis and Lung Diseases, 2017, vol. 95, no. 1, pp. 53–55. (In Russ.)
  2. Gorelov F.I. Surgical treatment for bronchial fistula after pneumonectomy. Khirurgia, 1985, no. 6, pp. 85–(In Russ.)
  3. Levin A.V., Tseimakh E.A., Zimonin P.E. The application of valve bronchial blockage in complicated pulmonary TB. Endoskopia, 2012, no. 1, pp. 15–17. (In Russ.)
  4. Nazyrov F.G., Khudaibergenov Sh.N., Pakhomov G.L. The peculiarities of treatment tactics in patients with bronchopleural fistula after pneumonectomy. Vestnik eksperimentalnoi i klinicheskoi khirurgii, 2010, no. 4, 305–307. (In Russ.)
  5. Naumov V.N., Shaikhaev A.Ya., Abramov E.L., Nezhmedenov A.P. Pneumonectomy in phthisiology. Problemsof Tuberculosis, 1991, no. 11, pp. 40–43. (In Russ.)
  6. Pechetov A.A., Gritsyuta A.Yu., Davydenko P.I. Transsternal occlusion of the main bronchus stump in bronchopleural fistula and non-specific pleural empyema. Khirurgia, 2019, no. 7, pp. 5–9. (In Russ.)
  7. Slobodenyuk I.F., Polezhaev A.A. Surgical treatment for bronchial fistula after pneumonectomy. Grudnaya i serdechno-sosudestaya khirurgia, 2012, no. 1, pp. 36–39. (In Russ.)
  8. Shilova M.V. Organization of TB service in Russia and ways to modernize organizational-methodical administration of dispensary follow-up of TB patients in the modern epidemic and socioeconomic conditions. Tuberculosis and Lung Diseases, The 9th congress of Russian phthisiologists, 2011, pp. 236–237. (In Russ.)
  9. Yablonsky P.K., Sokolovich E.G., Avetisyan A.O., Vasilyev I.V. The role of thoracic surgery in the management of pulmonary TB (a literature review and observations). Medithinsky Alyans, 2014, no. 3, pp. 4–10. (In Russ.)
  10. Andreetti C., Menna C., D’Andrilli A., Ibrahim M., Maurizi G., Poggi C., Fiorelli A. Multimodal treatment for postpneumonectomy bronchopleural fistula associated with empyema. The Annals of Thoracic Surgery, 2018, vol. 106, no. 6, pp. 337–339.
  11. Athanassiadi K., Kalavrouziotis G., Bellenis I. Bronchopleural fistula after pneumonectomy: a major challenge. Acta. Chir. Hung., 1999, vol. 38, no. 1, pp. 5–7. 12. Bai L., Hong Z., Gong C., Yan D., Liang Z. Surgical treatment efficacy in 172 cases of tuberculosisdestroyed lungs. Eur. J. Cardiothorac. Surg., 2011, vol. 41, no. 2, pp. 335–340.
  12. Botianu A.M., Botianu P.V. Modified thoraco-mediastinal  plication (Andrews thoracoplasty) for postpneumonectomy empyema: experience with 30 consecutive cases. Interact. Cardiovasc. Thorac. Surg., 2013, vol. 16, no. 2, pp. 173–177.
  13. Boudaya M.S., Smadhi H., Zribi H. Conservative management of postoperative bronchopleural fistulas. J. Thorac.Cardiovasc. Surg., 2013, vol. 146, pp. 575–579.
  14. Cardillo G., Carbone L., Carleo F., Galluccio G., Di Martino M., Giunti R. The rationale for treatment of postresectional bronchopleural fistula: analysis of 52 patients. Ann. Thorac. Surg., 2015, vol. 100, pp. 251–257.
  15. Deschamps C., Allen M.S., Miller D.L., Nichols F.C., Pairolero P.C. Management of postpneumonectomy empyema and bronchopleural fistula. Semin. Thorac. Cardiovasc. Surg., 2001, vol. 13, no. 1, pp. 13–19.
  16. Fukui T., Matsukura T., Wakatsuki Y., Yamawaki S. Simple chest closure of open window thoracostomy for postpneumonectomy empyema: a case report. Surg. Case Rep., 2019, vol. 5, no. 1, p. 53.
  17. Ginsberg R.J., Saborio D.V. Management of the recalcitrant postpneumonectomy bronchopleural fistula: the transsternal transpericardial approach. Semin. Thorac. Cardiovasc. Surg., 2001, vol. 13, no. 1, pp. 20–26.
  18. Gursoy S., Yazgan S., Ucvet A., Samancilar O., Unal M., Gulmez B., Sirzai E.Y. Post-pneumonectomy bronchopleural fistula in non-small cell lung cancer patients: incidence, survival, mortality, and treatment analysis. Surg. Today, 2018, vol. 48, no. 7, pp. 695–702.
  19. Icard P., Le Rochais J.P., Rabut B., Cazaban S., Martel B., Evrard C. Andrews thoracoplasty as a treatment of post-pneumonectomy empyema: experience in 23 cases. Ann. Thorac. Surg., 1999, vol. 68, no. 4, pp. 1159–1163.
  20. Inage T., Nakajima T., Fujiwara T., Murakami K., Uesato M., Matsubara H. Bronchial embolization with an endobronchial watanabe spigot for broncho-gastric tube fistula. Respiration. 2017, vol. 94, pp. 375–379. 22. Karapinar K., Saydam O., Metin M. Experience with vacuum-assisted closure in the management of postpneumonectomy empyema: an analysis of eight cases. Thorac. Cardiovasc. Surg., 2015, vol. 64, no. 3, pp. 258–262.
  21. Laserson K.F., Thorpe L.E., Leimane V. Speaking the same language: treatment outcome definitions for multidrug-resistant tuberculosis. Int. J. Tuberc. Lung. Dis., 2005, vol. 9, pp. 640–645.
  22. Mazzella A., Pardolesi A., Maisonneuve P., Petrella F., Galetta D., Gasparri R., Spaggiari L. Bronchopleural fistula after pneumonectomy: risk factors and management, focusing on open-window thoracostomy. Semin. Thorac.Cardiovasc. Surg., 2018, vol. 30, no. 1, pp. 104–113.
  23. Nicolaï M., Siat J., De Runz A., Brix M., Simon E. Use of pedicled dorsal muscle flap combined with negative pressure therapy in the management of postpneumonectomy septic complications. Ann. Chir.Plast. Esthet., 2019, pp. S0294-1260(19)30059-7.
  24. Scordamaglio P.R., Tedde M.L., Minamoto H., Assad R.S., Fernandes P.M.P. Can total bronchopleural fistulas from complete stump dehiscence be endoscopically treated. European Journal of Cardio-Thoracic Surgery, 2017, vol. 51, pp. 702–708.
  25. Spaggiari L., Galetta D. Video-thoracoscopic management of postpneumonectomy empyema. The Thoracic and Cardiovascular Surgeon Thorac. Cardiovasc. Surg., 2018, vol. 66, no. 8, pp. 701–706.
  26. Stern J.-B., Fournel L., Wyplosz B., Girard P., Nakib M., Gossot D., Seguin-Givelet A. Early and delayed postpneumonectomy empyemas: Microbiology, management and prognosis. The Clinical Respiratory Journal, 2017, vol. 12, no. 4, pp. 1753–1761.
  27. Yanagiya M., Matsumoto J., Nagano M., Kusakabe M., Matsumoto Y., Furukawa R., Ohara S., Usui K. Endoscopic bronchial occlusion for post-operative persistent bronchopleural fistula with computed tomography fluoroscopy guidance and virtual bronchoscopic navigation: A case report. Medicine (Baltimore), 2018, vol. 97, no. 7, p. 9921.
  28. Zeng Y., Gao H.Z., Zhang X.B., Lin H.H. Closure of bronchopleural fistula with mesenchymal stem cells: case report and brief literature review. Respiration, 2019, vol. 97, pp. 273–276.
KEYWORDS:

 tuberculosis, surgery, empyema, bronchial fistula, pneumonectomy.

FOR CORRESPONDENCE:

I.M. Sechenov 1st Moscow State Medical University

8–2, Trubetskaya St., 119991, Moscow, Russia

Dmitry B. Giller, Doctor of Medical Sciences, Professor, Head, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel.: +7 (916) 868-12-91

E-mail: Giller-thorax@mail.ru

Oleg Sh. Kesaev, Candidate of Medical Sciences, Docent, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel.: +7 (916) 410-39-28

E-mail: olegkesaeff@yandex.ru

Vadim V. Koroev, Candidate of Medical Sciences, Docent, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel.: +7 (925) 049-37-04

E-mail: koroeff.lancet@yandex.ru

Aleksey A. Glotov, Candidate of Medical Sciences, Docent, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel.: +7 (985) 363-04-33

E-mail: alexglot73@mail.ru 

Patiman G. Gadzhieva, Assistant, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel: +79967) 148-94-09

E-mail: schuldich9@yandex.ru

Egor M. Glotov, Postgraduate, Department of Phthisiopulmonology and Thoracic Surgery named after M.I. Perelman

Tel.: +7 (916) 826-58-56

E-mail: foxxxgtr13@yandex.ru

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Atadzhan E. Ergeshov, Doctor of Medical Sciences, Professor, Director

Tel.: +7 (499) 785-90-19

E-mail: cniit@ctri.ru

Ingush State University

39, Magistralnaya St., 386132, Nazran, Republic of Ingushetia

Yakub G. Imagozhaev, Candidate of Medical Sciences, Senior Teacher, Department of Hospital Therapy, Medical Faculty

Tel.: +7 (962) 641-09-89

E-mail: Cell_1980@mail.ru

Tambov Oblast TB Dispensary

Georgievsky village, 392513, Tambov oblast

 

Vadim A. Pekhtusov, Head of Department

Tel.: +7 (905) 048-51-62

E-mail: Vad-pekhtusov@yandex.ru

Republican Specialized Scientific and Practical Medical Center of Tuberculosis and Pulmonology

1, Mazhlisy St., 100086, Tashkent, Republic of Uzbekistan

Odilzhan N. Nematov, Head, Department of Thoracic Surgery

Tel.: + 998 946-476-074

E-mail: dr.odiljon@mail.ru

THE PREVENTION OF POST-PNEUMONECTOMY MEDIASTINAL LUNG HERNIATION BY INTRAOPERATIVE ANTERIOR MEDIASTINAL PLASTY IN PATIENTS WITH DESTRUCTIVE PULMONARY TB AND THE EVALUATION OF ITS EFFECT ON RESPIRATORY FUNCTIONS

Article 7.

Page 60.

ARTICLE TITLE:

THE PREVENTION OF POST-PNEUMONECTOMY MEDIASTINAL LUNG HERNIATION BY INTRAOPERATIVE ANTERIOR MEDIASTINAL PLASTY IN PATIENTS WITH DESTRUCTIVE PULMONARY TB AND THE EVALUATION OF ITS EFFECT ON RESPIRATORY FUNCTIONS

 DOI: 10.7868/S2587667820020077

AUTORS:

Ergeshova A.E.1, Krasnikova E.V.1, Penagi R.A.1, Salikhov B.U.2, Chitorelidze G.V.1, Tarasov R.V.1, Bagirov M .A.1

1 Central TB Research Institute, Moscow, Russia

2 Oblast Clinical TB Hospital, Kaluga, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 16.03.2020

We analyzed the outcomes of anterior mediastinal plasty for the prevention of mediastinal herniation after pneumonectomy in 91 patients with destructive pulmonary TB. We compared surgery outcomes in 49 (53.8%) patients after pneumonectomy with anterior mediastinal plasty, with outcomes in 42 (46.2%) patients after pneumonectomy without additional interventions. The study demonstrated the effectiveness of anterior mediastinal plasty for the prevention or reduction or size retention of pre-operative mediastinal lung hernias. We also observed decreased dyspnea and improved respiratory functions in patients after intraoperative anterior mediastinal plasty.

The study was conducted under research topic no. 0515-2019-0017 “The development of surgical methods for treatment of advanced pulmonary TB and bone and joint TB”.

REFERENCES:
  1. Bagirov M.A., Ibriev A.S., Krasnikova E.V., Sadovnikova S.S., Tokaev K.V., Tokaev T.K., Ergeshov A.E. The method of prevention of post-pneumonectomy syndrome. Patent for invention no. RU 2614525от30.11.2015. (In Russ.)
  2. Perelman M.I., Naumov V.N., Dobkin V.G. et al. The indications for surgery in pulmonary TB patients. The methodical recommendations of Central TB Research Institute, Phthisiopulmonology Research Institute, Moscow Research and Clinical Center for Tuberculosis Control. Moscow, 2000, 25 p. (In Russ.)
  3. Radionov B.V., Savenkov Yu.F. The main variants and the peculiarities of anatomical and topographic changes in the chest after pneumonectomy. In: Pneumonectomy (indications, operational, technical and clinical aspects). Dnepropetrovsk, 2003, 308 p. (In Russ.)
  4. Serbinenko N.G., Makarov A.V., Savenkov Yu.F., Kalibukha I.A., Khmel O.V. The assessment of the external respiration function in patients in the remote period after pneumonectomy. Klinichna khirurgia, 2001,no. 1, pp. 22–23. (In Russ.)
  5. Chuchalin A.G., Avdeev S.N., Aisanov Z.R., Belevsky A.S., Leshchenko I.V., Meshcheryakova N.N.,  Ovcharenko S.I., Shmelev E.I. Russian Respiratory Society. The federal clinical recommendations on diagnosis and treatment of chronic obstructive pulmonary disease. Pulmonologia, 2014, no. 3, pp. 15–54. (In Russ.) https://doi.org/10.18093/0869-0189-2014-0-3-15-54
  6. Shalimov A.A., Slepukha I.M., Vashchenko A.E. et al. The remote result of pneumonectomy for TB and chronic non-specific pulmonary diseases. Klinichnakhirurgia, 1995, no. 11–12, pp. 3–5. (In Russ.)
  7. The epidemic situation of TB in Russia in 2018. The federal centre of TB control monitoring in the Russian Federation. (In Russ.) [Electronic resource]. Mode of access: https://mednet.ru/images/materials/CMT/2018_god_tuberkulez_epidsituaciya.pdf
KEYWORDS:

TB, pneumonectomy, mediastinal lung hernia, anterior mediastinal plasty, respiratory function.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Anush E. Ergeshova, Thoracic Surgeon, Surgery Unit No. 2, Surgery Department

Теl: +7 (499) 785-90-76

E-mail: dr.akhachatryan@mail.ru

Elena V. Krasnikova, Doctor of Medical Sciences, Senior Researcher, Head of Operating Unit, Surgery Department

Tel: +7 (499) 785-91-96

E-mail: el.krasn@gmail.com

Ramil Nidzhat A. Penagi, Junior Researcher, Thoracic Surgeon, Surgery Unit No. 2, Surgery Department

Tel.: +7 (499) 785-90-76

E-mail: ramilpenagi@gmail.com 

George V. Chitorelidze, Thoracic Surgeon, Surgery Unit No. 2, Surgery Department

Tel.: +7 (499) 785-90-76

E-mail: chitorelidze2015@yandex.ru

Ruslan V. Tarasov, Junior Researcher, Surgeon, Surgery Unit No. 1, Surgery Department

Теl.: +7 (499) 785-91-96

E-mail: etavnai@yandex.ru 

Mamad-Bagir A. Bagirov, Doctor of Medical Sciences, Head, Surgery Department

Tel.: +7 (499) 748-30-14

E-mail: bagirov60@gmail.com

Kaluga Oblast Clinical TB Hospital

85, Maksim Gorky St., 248003, Kaluga, Russia

Bekhruz U. Salikhov, Head, TB Surgery Department

Tel.: +7 (910) 513-51-68

E-mail: bekhruz80@gmail.com

DIFFERENT ASPECTS OF THE INTERNAL PICTURE OF THE DISEASE IN ADOLESCENTS WITH PULMONARY TB

Article 8.Page 68.
ARTICLE TITLE:

DIFFERENT ASPECTS OF THE INTERNAL PICTURE OF THE DISEASE IN ADOLESCENTS WITH PULMONARY TB

DOI: 10.7868/S2587667820020089

AUTORS:

Zolotova N.V., Akhtyamova A.A.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 30.03.2020

The aim of the study was to investigate different components of the internal picture of the disease (IPD) in adolescents with pulmonary TB and their parents. The study enrolled 83 patients aged 13–17, who received treatment at the adolescent department of Central TB Research Institute in 2016–2019, and 41 parents. We investigated different aspects of IPD at admission to hospital using a special questionnaire. We established that the intellectual level before treatment was characterized by lack of awareness about the disease, terms and peculiarities of treatment, and favourable assessment of treatment prospects. The motivation level in adolescents was characterized by negative attitude towards the status of “TB patient”. The emotional component of IPD was most expressed in both adolescents and their parents and characterized by tense attitude towards upcoming TB treatment, fear of a changing position in the social environment, perception of the disease as an obstacle to the achievement of significant goals.

The study was conducted under research topic no. АААА-А16-116111150009-0 “Personalized approaches to pulmonary TB treatment in children and adolescents”.

REFERENCES:
  1. Bondarenko S.M., Smirnov V.V., Danilenko O.V., Petryaikina E.E. The peculiarities of the internal picture of the disease in children and adolescents with type 1 diabetes mellitus. Pediatria, 2006, no. 4, pp. 22–27. (In Russ.)
  2. Gromyko E.V., Sokolova E.A. The historical aspect of the internal picture of the disease (a literature review). Problemy zdorovya i ekologii, 2012, no. 1 (31), pp. 37–44. (In Russ.)
  3. Danikov D.S. Therapeutical cooperation (compliance): concept, mechanisms of development and methods of optimization. Nevrologia, neiropsikhiatria, psikhosomatika, 2014, no. 2, pp. 4–12. (In Russ.)
  4. Isaev D.N. Medical child psychology. Psychological paediatrics. St. Petersburg, Rech, 2004, 384 p. (In Russ.)
  5. Kurtanova Yu.L. The internal picture of the disease in children with different somatic diseases. Voprosy psikhicheskogo zdorovia detei i podrostkov, 2003, no. 3 (2), pp. 16–21. (In Russ.)
  6. Luriya R.A. The internal picture of the disease and iatrogenic diseases. Moscow, Meditsina, 1977, pp. 37–(In Russ.)
  7. Nikolaeva V.V. The influence of a chronic disease on the psychic. Moscow, 1987, 168 p. (In Russ.)
  8. The questionnaire: only one third of Russians know about anti-tuberculosis vaccine. (In Russ.) [Electronic resource]. Mode of access: https://tass.ru/obschestvo/8060731
  9. Savenich N.V. The internal picture of the disease in adolescents with different types of TB. Molodoi ucheny,2017, no. 49, pp. 430–433. (In Russ.)
  10. Svistunova E.I. How does a child perceive illness? Meditsinskaya sestra, 2012, no. 2, (In Russ.)
KEYWORDS:

TB, adolescents, adherence to treatment, internal picture of a disease.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Natalia V. Zolotova, Candidate of Psychological Sciences, Senior Researcher, Laboratory

of Psychological Issues in TB, Phthisiology Department

Tel.: +7 (499) 785-91-54

Е-mail: Zolotova_n@mail.ru

Almira A. Akhtyamova, Candidate of Psychological Sciences, Senior Researcher, Laboratory of Psychological Issues in TB, Phthisiology Department

Tel. +7 (499) 785-90-05

Е-mail: bliznec18@bk.ru

THE RESULTS OF IMMUNODIAGNOSTICS OF TUBERCULOSIS IN PATIENTS ADMITTED TO A GENERAL HOSPITAL PULMONOLOGY DEPARTMENT

Article 9.Page 74.
ARTICLE TITLE:

THE RESULTS OF IMMUNODIAGNOSTICS OF TUBERCULOSIS IN PATIENTS ADMITTED TO A GENERAL HOSPITAL PULMONOLOGY DEPARTMENT

DOI: 10.7868/S2587667820020090

AUTORS:

Nebesnaya E.Yu.1, Bakhshieva L.I.1, Bagisheva N.V.1, Dubrovskaya I.I.2, Zenkova L.A.3, Mordyk D.I.4, Moiseeva M.V.1

1 Omsk State Medical University, Omsk, Russia

2 Emergency Hospital No. 2, Omsk, Russia

3 City Clinical Hospital No. 11, Omsk, Russia

4 Main Bureau of Medical and Social Expertise for Omsk Oblast, Omsk, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 24.12.2019

The article discusses the issues of early detection of tuberculosis and the role of the Mantoux test and the Diaskintest in differential diagnosis of tuberculosis in patients admitted to the pulmonology department of a multidisciplinary emergency hospital. We analyzed 103 medical records. The obtained data revealed significant correlation between positive reactions to the Mantoux test with 2 TU or the Diaskintest and frequency of tuberculosis detection.

REFERENCES:
  1. Aksenova V.A., Levi D.T., Aleksandrova N.V., Kudlay D.A. Current tuberculosis incidence among children. BIOpreparations. Prevention, Diagnosis, Treatment, 2017, vol. 17, no. 3, pp. 145–151. (In Russ.)
  2. Borodulina E.A., Borodulin B.E., Inkova T.A., Vdoushkina E.S., Povalyaeva L.V. Some opportunities of TB diagnosis in a hospital pulmonology department. Pulmonologia, 2019, no. 3, pp. 321–326. (In Russ.)
  3. Vasilyeva I.A., Belilovsky E.M., Borisov S.E., Sterlikov S.A. Incidence, mortality and prevalence as indicators of tuberculosis burden in the WHO regions, countries of the world and the Russian Federation. Tuberculosis and Lund Diseases, 2017, no. 6 (95),pp. 9–21. (In Russ.)
  4. Kravchenko E.N., Mordyk A.V., Valeeva G.A., Puzyreva L.V. The aspects of pregnancy termination in women with active pulmonary TB. Akusherstvo i ginekologia, 2014, no. 8, pp. 100–105. (In Russ.)
  5. Kravchenko E.N., Mordyk A.V., Valeeva G.A., Puzyreva L.V. Reproductive health of women with active pulmonary TB. Doktor.Ru, 2015, no. 1 (102), pp. 5–8. (In Russ.)
  6. Mordyk A.V., Bagisheva N.V., Ivanova O.G., Batishcheva T.L., Bekmukhambetova N.V. Clinical and epidemiological features of upper and lower respiratory tract tuberculosis in patients with chronic nonspecific lung diseases. Folia Otorhinolaringologiae et Pathologiae Respiratoriae, 2016, vol. 22, no. 1, pp. 84–90. (In Russ.)
  7. Mordyk A.V., Ivanova O.G., Sitnikova S.V. HIV-associated TB: the causes of treatment failure. Omsky nauchny vestnik, 2015, no. 2 (144), pp. 23–26. (In Russ.)
  8. Mordyk A.V., Ivanova O.G., Sulim D.A., Bagisheva N.V. Chronic obstructive pulmonary disease and concomitant infectious disease. Lechashchy vrach,2014, no. 10, pp. 14–16. (In Russ.)
  9. Nechaeva O.B. The epidemiological situation of TB in Russia. Tuberculosis and Lung Diseases, 2018, no. 8 (96), pp. 15–24. (In Russ.)
  10. Puzyreva L.V., Mordyk A.V., Tatarintseva M.P., Rudneva S.N. The contribution of HIV infection into development of the epidemiological situation of TB in Western Siberian region. Dalnevostochny medithinsky zhurnal, 2017, no. 4, pp. 36–40. (In Russ.)
  11. Romanova M.A., Mordyk A.V. The impact of age and comorbidities on the structure of clinical TB, detection method and immunological skin test results. Zabaikalsky meditsinsky vestnik, 2015, no. 3, pp. 67–72. (In Russ.)
  12. Rudenko S.A., Mordyk A.V., Bagisheva N.V., Emelyanova Yu.A. The comparative aspects of bacteriology diagnosis, course and treatment outcomes of newly detected TB – solitary or associated with chronic obstructive pulmonary disease. Kursky nauchnopraktichesky vestnik ”Chelovek i ego zdorovie”, 2017, no. 3, pp. 49–54. (In Russ.)
  13. Samorodov N.A., Kibishev V.M., Tilova L.A., Savanchieva Zh.Kh., Pavlova M.V., Safonova V.V., Bolotokova A.V. The analysis of recombinant tuberculosis allergen Diaskintest results in patients with pulmonary diseases. Vestnik novykh meditsinskikh tekhnologii,2019, no. 2, pp. 114–119. (In Russ.)
  14. Seregina V.A., Budritsky A.M. Modern opportunities of diagnosis of pulmonary TB. Vestnik VGMU, 2016, vol. 15, no. 4, pp. 7–17. (In Russ.)
  15. Skornyakov S.N., Shulgina M.V., Zhuravlev V.Yu., Totolyan A.A. Phthisiology. National clinical recommendations. Moscow, 2015, 240 p. (In Russ.)
  16. Skornyakov S.N., Shulgina M.V., Ariel B.M., Balasanyants G.S. Clinical recommendations on tuberculosis etiology diagnosis. Meditskinsky alyans, 2014, no. 3, pp. 39–58. (In Russ.)
  17. Tuberculosis. World Health Organization. URL: https://www.who.int/ru/news-room/fact-sheets/detail/tuberculosis (date of referral: 02.04.2019).
  18. Mendez-Samperio P. Diagnosis of tuberculosis in HIV co-infected individuals: current status, challenges and opportunities for the future. Scand. J. Immunol., 2017, vol. 86, no. 2, pp. 76–82.
  19. Nikitina I.Y., Karpina N.L., Kasimceva O.V., Gergert V.Y. Comparative performance of QuantiFERON-TB Gold versus skin test with tuberculosis recombinant allergen (Diaskintest) among patients with suspected pulmonary tuberculosis in Russia. Int. J. Infect. Dis., 2019, vol. 86, pp. 18–24.
  20. Starshinova A., Zhuravlev V., Dovgaluk I., Panteleev A. A comparison of intradermal test with recombinant tuberculosis allergen (diaskintest) with other immunologic tests in the diagnosis of tuberculosis infection Int. J. Mycobacteriol., 2018, vol. 7, no. 1, pp. 32–39.
KEYWORDS:

tuberculosis, Mantoux test, diaskintest, tuberculosis control measures, Mycobacterium tuberculosis, chest fluorography.

FOR CORRESPONDENCE:

Omsk State Medical University

12, Lenin St., 644099, Omsk, Russia

Ekaterina Yu. Nebesnaya, Sixth-year Student, Faculty of Medicine

Tel.: +7 (913) 689-10-59

Е-mail: nebesnay_katya97@mail.ru

Leyla I. Bakhshieva, Sixth-year Student, Faculty of Medicine

Tel.: +7 (908) 102-60-98

Е-mail: butter27fly@mail.ru

Natalia V. Bagisheva, Candidate of Medical Sciences, Assistant, Department of Internal Diseases and Polyclinic Therapy

Tel.: +7 (923) 672-00-20

Е-mail: ppi100@mail.ru

Marina V. Moiseeva, Candidate of Medical Sciences, Assistant, Department of Internal Diseases and Polyclinic Therapy

Tel.: +7 (913) 607-43-42

Е-mail: lisnyak80@mail.ru

Emergency Hospital No. 2

3, L. Chaikina St., 644021, Omsk, Russia

Irina I. Dubrovskaya, Head, Pulmonology Department

Tel.: +7 (3812) 32-19-15

Е-mail: gkbsmp2@yandex.ru

City Clinical Hospital No. 11

55, Nakhimov St., 644105, Omsk, Russia

Ludmila A. Zenkova, Head, Pulmonology Department

Tel.: +7 (3812) 28-43-94

Е-mail: muzgkb11@mail.ru

Main Bureau of Medical and Social Expertise for Omsk Oblast 74, 10 let Oktyabrya St., 644070, Omsk, Russia

Dmitry I. Mordyk, Expert Physician

Tel.: +7 (3812) 53-12-36

Е-mail: gbmse55@fbmse.ru

A COMPLEX APPROACH TO TREAT MENT OF A CHILD WITH DELAYED DIAGNOSIS OF HOUSEHOLD ACQUIRED MULTIDRUG RESISTANT PULMONARY TB

Article 10.Page 82.
ARTICLE TITLE:

A COMPLEX APPROACH TO TREATMENT OF A CHILD WITH DELAYED DIAGNOSIS OF HOUSEHOLD ACQUIRED MULTIDRUG RESISTANT PULMONARY TB

DOI: 10.7868/S2587667820020107

AUTORS:

Gubkina M.F.1,2, Sterlikova S.S.1, Petrakova I.Yu.1, Khokhlova Yu.Yu.1, Yukhimenko N.V.1

1 Central TB Research Institute, Moscow, Russia

2 Russian National Research Medical University named after N.I. Pirogov, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 21.02.2020

The article describes a clinical observation of delayed diagnosis of household acquired multidrug resistant (MDR) pulmonary TB in a child. Delayed diagnosis was preconditioned by both inadequate follow-up of household contacts and poor adherence to treatment of the child’s parents. Combination of chemotherapy based on drug susceptibility and tolerance of TB drugs with surgery allowed to achieve clinical cure with minimal residual changes.

The study was conducted under research topic no. 0515-2019-0016 “Personalized approaches to pulmonary TB treatment in children and adolescents”.

REFERENCES:
  1. Abildaev T.Sh., Bekembaeva G.S., Kastykpaeva L.Z. The main risk factors of TB in drug resistant TB infection sources. Tuberculosis and Lung Diseases, 2014,no. 3, pp. 33–35. (In Russ.)
  2. Aksenova V.A., Klevno N.I., Kavtarashvili S.M., Kazakov A.V., Pakhlavonova A.D. TB infection source as a risk of developing multidrug resistant TB in children. Tuberculosis and Lung Diseases, 2018, no. 1, pp. 11–17. (In Russ.)
  3. Aksenova V.A., Klevno N.I., Kazakov A.V., Gordina A.V., Fatykhova R.Kh. Preventive chemotherapy in children from multidrug resistant TB infection sources. Tuberculosis and Lung Diseases, 2019, no. 6, 36–43. (In Russ.)
  4. Gubkina M.F., Khokhlova Yu.Yu., Ovsyankina E.S., Petrakova I.Yu., Yukhimenko N.V., Zolotova N.V., Akhtyamova A.A. Social characteristics of TB infection sources. Tuberculosis and Lung Diseases, 2018, 2, pp. 59–60. (In Russ.)
  5. Gubkina M.F., Khokhlova Yu.Yu., Yukhimenko N.V., Petrakova I.Yu. Personalized approaches to chemotherapy regimen choice in treating children with pulmonary TB from epidemic multidrug TB infection sources. Tuberculosis and Lung Diseases, 2016, no. 9, pp. 24–29. (In Russ.)
  6. Gubkina M.F., Sterlikova S.S. The role of screening methods in TB detection in children. CTRI Bulletin, 2019, no. 3 (8), pp. 13–19. (In Russ.)
  7. Lozovskaya M.E., Kurova A.S., Vasilyeva E.B., Klochkova L.V., Nikoforenko N.A., Mosina A.V. The peculiarities of clinical course and chemotherapy of TB in children from infection sources with different spectra of drug sensitivity. Tuberculosis and Lung Diseases,2019, no. 9, pp. 22–27. (In Russ.)
  8. Panova L.V., Ovsyankina E.S., Giller D.B., Kobulashvili M.G. The algorithms of treatment of destructive pulmonary TB in older children and adolescents (newly diagnosed and retreatment cases). Tuberculosis and Lung Diseases, 2014, no. 1–2, pp. 121–126. (In Russ.)
  9. Parolina L.E., Barinboin O.N., Laktorova N.P. Adherence to treatment among newly diagnosed patients with drug resistant TB. Tuberculosis and Lung Diseases, 2011, no. 5, pp. 100–101. (In Russ.)
  10. Repina O.V., Skornyakova S.N., Golubkova A.A. On the question of TB incidence among household TB contacts. Journal of Ural Medical Academic Science, 2015, no. 1, pp. 3–17. (In Russ.)
  11. Starshinova A.A. TB diagnostics in children from household infection sources using modern immunological and radiological methods. Prakticheskayameditsina, 2012, no. 1 (56), pp. 74–76. (In Russ.)
  12. Starshinova A.A., Dovralyuk I.F., Pavlova M.V. High risk factors of developing TB in children from household infection sources. Tuberculosis and Lung Diseases,2014, no. 8, pp. 62–63. (In Russ.)
  13. TB in the Russian Federation in 2012/2013/2014. The analytical review of statistical rates of TB used in the Russian Federation and in the world. Moscow, 2015, 312 p. (In Russ.)
KEYWORDS:

TB, children, infection source, multidrug resistance, chemotherapy, complex treatment.

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Russian National Research Medical University named after N.I. Pirogov

1, Ostrovityanova St., 117997, Moscow, Russia

Marina F. Gubkina, Doctor of Medical Sciences, Leading Researcher, Child and Adolescent Department, Central TB Research Institute; Professor, Phthisiology Department, Russian National Research Medical University named after N.I. Pirogov

Tel.: +7 (499) 785-90-27

E-mail: detstvocniit@mail.ru

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Svetlana S. Sterlikova, TB Physician, Junior Unit, Child and Adolescent Department

Tel.: +7 (499) 785-90-27

E-mail: detstvocniit@mail.ru 

Irina Yu. Petrakova, Candidate of Medical Sciences, Head, Junior Unit, Child and Adolescent Department

Tel.: +7 (499) 785-90-27

E-mail: detstvocniit@mail.ru

Yulia. Yu. Khokhlova, TB Physician, Junior Unit, Child and Adolescent Department

Tel.: +7 (499) 785-90-27

E-mail: detstvocniit@mail.ru

Natalya V. Yukhimenko, Doctor of Medical Sciences, Leading Researcher, Child and Adolescent Department

Tel.: +7 (499) 785-90-27

E-mail: detstvocniit@mail.ru

DETECTION OF MYCOBACTERIA BY CULTURE INOCULATION. DECONTAMINATION OF DIAGNOSTIC SAMPLES

Article 11.Page 89.
ARTICLE TITLE:

DETECTION OF MYCOBACTERIA BY CULTURE INOCULATION. DECONTAMINATION OF DIAGNOSTIC SAMPLES

DOI: 10.7868/S2587667820020119

AUTORS:

Sevastyanova E.V., Larionova E.E., Andrievskaya I.Yu., Smirnova T.G.

Central TB Research Institute, Moscow, Russia

DESCRIPTION OF ARTICLE:

Submitted as of 18.03.2020

We reviewed the existing methods of pre-treatment before inoculation of diagnostic samples for mycobacteria detection. We outlined the main principles and recommendations on pre-treatment of diagnostic samples. We also described the most relevant methods of decontamination of diagnostic samples.

The article was prepared under research topic no. 0515-2019-0015: “The development of drug resistance of mycobacteria and somatic cells to TB drugs”.

REFERENCES:
  1. Tuberculosis Laboratory Maintenance Plan (LMP) for preventive and routine maintenance of laboratory equipment. WHO/Europe, 2017. (In Russ.) http:// www.euro.who.int/__data/assets/pdf_file/0010/355789/ WHO-ELI-TB-Lab-Maintenance-Plan_RUS.PDF.
  2. Fedorova L.S., Yuzbashev V.G., Popov S.A., Puzanov V.A., Sevastyanova E.V., Akimkin V.G., Frolova N.V., Myasnikova E.B., Volchenkov G.V., Pronkov V.A., Nagolkin A.V. Infection control system in TB units: Guidelines. Ed. by L.S. Fedorova, Moscow-Tver, Triada, 2013, 192 p. (In Russ.)
  3. Chernousova L.N., Puzanov V.A., Andreevskaya S.N., Smirnova T.G., Larionova E.E., Popov S.A. Laboratory diagnosis of TB. In: Methodical materials for thematic improvement cycle. Ed. by V.V. Erokhin, Moscow, 2012, 707 p. (In Russ.)
  4. Chernousova L.N., Sevastyanova E.V., Larionova E.E., Smirnova T.G., Andreevskaya S.N., Popov S.A., Zhuravlev V.Yu., Puzanov V.A., Maryandyshev A.O., Vakhrusheva D.V., Kravchenko M.A., Safonova S.G., Vasilyeva I.A., Ergeshov A.E. Federal clinical recommendations on organization and implementation of microbiological and molecular genetic diagnostics of TB. Moscow, RSPh, 2015, 35 p. (In Russ.)
  5. Angeby K.A., Hoffner S.E., Diwan V.K. Should the ‘bleach microscopy method be recommended for improved case detection of tuberculosis? Literaturereviewand key person analysis. Int. J. Tuberc. Lung Dis., 2004, no. 8, pp. 806–815.
  6. Asmar S., Drancourt M. Chlorhexidine decontamination of sputum for culturing Mycobacterium tuberculosis. BMC Microbiol., 2015, vol. 5, no. 15, p. 155.doi: 10.1186/s12866-015-0479-4
  7. British Thoracic Society. Guidelines for the management of non-tuberculosis mycobacteria pulmonary disease (NTM-PD). British Thoracic Society NTM Guideline Development Group, 2018.
  8. Chakravorty S., Tyagi J.S. Novel multipurpose methodology for detection of mycobacteria in pulmonary and extrapulmonary specimens by smear microscopy, culture, and PCR. J. Clin. Microbiol., 2005, no. 43, pp. 2697–2702.
  9. Ganoza С.A., Ricaldi J.N., Chauca J., Rojas G., Munayco C., Agapito J., Palmino J.C. and Guerrf H. Novel hypertonic saline-sodium hydroxide (HS-SH) method for decontamination and concentration of sputum samples for Mycobacterium tuberculosis microscopy and culture. Journal of Medical Microbiology, 2008, no. 57,pp. 1094–1098. DOI 10.1099/jmm.0.2008/001339-0
  10. Coronel J.E., Del Carpio C.C., Dianderas E.J., Florentini E.A., Kemper G.L., Sheen P., Zimic M.J. Evaluation of microbiological variants of sputum processing and concentration of mycobacteria to optimize the microscopic and imaging diagnosis of tuberculosis. Int. J. Mycobacteriol., 2019, no. 8 (1), pp. 75–82.doi: 10.4103/ijmy.ijmy_172_18
  11. Daley P., Michael J.S., Latha A., Mathai D. et al. A Pilot Study of Short-duration sputum pretreatment procedures for optimizing smear microscopy for tuberculosis. PLoS ONE, 2009, no. 4 (5), p. e5626. doi: 10.1371/journal.pone.0005626
  12. Desalegn Addise, Adane Bitew, Zelalem Yaregal, Bazezew Yenew, Helina Mollalign, Getu Diriba, and Abebaw Kebede. Effect of 1.5% sodium hydroxide final concentration on recovery rate of mycobacterial species and decontamination of other bacterial and fungal contaminants on sputum. Ethiop. J. Public Health Nutr., 2016, no. 1 (1), pp. 57–67. 13. Ensa Gitteh, Jacob Kweku Otu, Tijan Jobarteh, Francis Mendy, Isatou Tutty Faal-Jawara, Nana Boatema Ofori-Anyinam, Abigail Ayorinde, Ousman Secka, Florian Gehre. Evaluation of sodium hydroxide-N-acetyl-L-cysteine and 0.7% chlorhexidine decontamination methods for recovering Mycobacterium tuberculosis from sputum samples: A comparative analysis (The Gambia Experience). International Journal of Mycobacteriology, 2016, no. 5, pp. S167–S168.
  13. European Centre for Disease Prevention and Control. Handbook on TB laboratory diagnostic methods for the European Union, Stockholm: ECDC; 2016. Stockholm, 2016, ISBN 978-92-9193-739-4.doi 10.2900/216384
  14. Iseman M.D. A clinician’s guide to tuberculosis. PA, Lippincott Williams and Wilkins, 2000, 460 p.
  15. Kent P.T., Kubica G.P. Public health mycobacteriology: a guide for the level III laboratory. Atlanta, Centers for Disease Control, 1985.
  16. Peres R.L., Maciel E.L., Morais C.G., Ribeiro F.C.K., Vinhas S.A., Pinheiro C., Dietze R., Johnson J.L., Eisenach K., Palaci M. Comparison of two concentrations of NALC-NaOH for decontamination of sputum for mycobacterial culture. J. Tuberculosis Dis., no. 13 (12), pp. 1572–1575.
  17. Perkins M.D. New diagnostic tools for tuberculosis. Int. J. Tuberc. Lung Dis., 2000, no. 4 (suppl. 2), pp. S182–188. Tuberculosis Control India. http://www.tbcindia.org
  18. Quincó P., Bührer-Sékula S., Brandão W., Monte R., Souza S.L., Saraceni V. et al. Increased sensitivity in the diagnosis of tuberculosis in HIV-positive patients through the small-membrane-filter method of microscopy. J. Clin. Microbiol., 2013, no. 51, pp. 2921–2925.
  19. Satapathy P., Das D., Murmu B.N., Kar S.K. Decontamination of sputum for longer time in sodium hydroxide for isolation of Mycobacterium tuberculosis. International Journal of Mycobacteriology, vol. 3, no. 4, pp. 290–292. doi.org/10.1016/j.ijmyco.2014.09.006
  20. Sohail M. Tuberculosis: A re-emerging enemy. J. Mol.Genet. Med., 2006, no. 2, pp. 87–88.
  21. Steingart K.R., Ng V., Henry M., Hopewell P.C., Ramsay A., Cunningham J. et al. Sputum processing methods to improve the sensitivity of smear microscopy for tuberculosis: A systematic review. Lancet Infect. Dis., 2006, no. 6, pp. 664–674.
  22. Trebucq A. Revisiting sputum smear microscopy. Int.J. Tuberc. Lung Dis., 2004, no. 8, p. 805.
  23. Van Deun A., Maug A.K., Cooreman E. et al. Bleach sedimentation method for increased sensitivity of sputum smear microscopy: does it work? Int. J. Tuberc. Lung Dis., 2000, no. 4, pp. 371–376.
  24. World Health Organization. Global Tuberculosis Report. Geneva, WHO, 2018. Available from: http://www.apps.who.int/iris/bitstream/handle/10665/274453/9789241565646‑eng.pdf. (Last accessed on 2018 Dec 15).
KEYWORDS:

mycobacteria, culture inoculation, diagnostic samples, decontamination

FOR CORRESPONDENCE:

Central TB Research Institute

2, Yauzskaya alley, 107564, Moscow, Russia

Elina V. Sevastyanova, Doctor of Biological Sciences, Leading Researcher, Microbiology Department

Tel.: +7 (499) 785-90-91

Е-mail: elinasev@yandex.ru

Elena E. Larionova, Candidate of Biological Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785-90-91

E-mail: larionova_lena@mail.ru 

Irina Yu. Andrievskaya, Researcher, Microbiology Department

Tel.: +7 (499) 785-90-91

Е-mail: andrievskaya.iri@mail.ru 

Tatiana G. Smirnova, Candidate of Medical Sciences, Senior Researcher, Microbiology Department

Tel.: +7 (499) 785-90-91

Е-mail: s_tatka@mail.ru

IN MEMORY OF VICTOR PETROVICH FILIPPOV

Article 12.Page 100.
ARTICLE TITLE:

IN MEMORY OF VICTOR PETROVICH FILIPPOV

AUTORS: 
DESCRIPTION OF ARTICLE:

10 апреля 2020 г. на 92‑м году ушел из жизни ветеран ФГБНУ ≪ЦНИИТ≫ доктор медицинских наук, профессор, Заслуженный деятель науки Российской Федерации Виктор Петрович Филиппов.

В.П. Филиппов родился 24 марта 1928 г. в г. Коломне. В 1951 г. он окончил Первый Московский медицинский институт, а в 1952 г. – военно-медицинский факультет при Куйбышевском медицинском институте. После окончания института до 1956 г. В.П. Филиппов служил в рядах Советской Армии в качестве врача медсанчасти. Демобилизовавшись, В.П. Филиппов поступил в клиническую ординатуру при Московском институте туберкулеза Минздрава РСФСР, где учился с 1956 по 1958 г. По окончании ординатуры в течение года он работал хирургом в главной противотуберкулезной больнице МВД СССР, а с ноября 1959 г. по приглашению акад. Л.К. Богуша Виктор Петрович начал работать в хирургическом отделении ЦНИИТ Минздрава СССР. После защиты кандидатской диссертации в 1964 г. на тему ≪Опыт клинического применения аппарата УКЛ при резекции легких у больных туберкулезом≫ В.П. Филиппов был назначен руководителем бронхологического отделения ЦНИИТ Минздрава СССР. Продолжая работать в тесном сотрудничестве с акад. Л.К. Богушем, В.П. Филиппов много времени уделял бронхологическим исследованиям больных хирургического отделения, прошел специализацию по эндоскопическим исследованиям бронхов в Германии у проф. Фриделя (г. Лоетау). В 1970 г. В.П. Филиппов защитил докторскую диссертацию на тему ≪Клиническое значение бронхологических исследований под наркозом≫. В.П. Филиппов стал одним из ведущих специалистов страны в области бронхологической инструментальной диагностики заболеваний органов дыхания. Он впервые в СССР разработал и внедрил в практику методику поднаркозной бронхоскопии и комплексной бронхобиопсии при различных заболеваниях легких, доказал целесообразность и эффективность трансбронхиальной биопсии легкого под рентгентелевизионным контролем и бронхоальвеолярного лаважа при диссеминированных заболеваниях легких. Его исследования по эндоскопическим вмешательствам нашли широкое применение во фтизиопульмонологии. В 1980 г. В.П. Филиппову было присвоено звание профессора. С 1975 по 2002 г. он возглавлял работу клинико-диагностического отдела ЦНИИТ РАМН, принимал участие в работе съездов фтизиатров и конгрессах по фтизиопульмонологии в нашей стране, а также странах Европы, где пропагандировал достижения отечественной медицины.

В.П. Филиппов опубликовал более 250 научных работ, в том числе 3 монографии: ≪Бронхологические исследования в дифференциальной диагностике туберкулеза≫ (1979), ≪БАЛ при

дифференциальных поражениях легких≫ (2006) и ≪Бронхоскопия при заболеваниях легких≫ (2014),

он соавтор ряда монографий (≪Туберкулез органов дыхания≫, ≪Саркоидоз≫, ≪Клиническая эндоскопия ≫), статей в медицинских энцикопедиях и методических указаний по различным видам эндоскопической биопсии и лазерной технологии.

Под руководством профессора В.П. Филиппова были подготовлены и успешно защищены 35 диссертаций, в том числе 3 докторские. Виктор Петрович щедро делился своим богатым профессиональным опытом, он стал учителем для многих высококвалифицированных эндоскопистов‑бронхологов, которые продолжают работать в России и странах ближнего зарубежья. За медицинскую и общественную деятельность профессор В.П. Филиппов был удостоен почетного звания Заслуженный деятель науки Российской Федерации≫ (1996) и ряда правительственных наград.

Светлую память о Викторе Петровиче будут хранить многие его ученики и люди, работавшие с ним в ЦНИИТ долгие годы. Администрация и сотрудники ФГБНУ ≪ЦНИИТ≫ выражают соболезнование семье и близким В.П. Филиппова.

REFERENCES: 
KEYWORDS:

Necrologue

FOR CORRESPONDENCE: